<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006888.pub2" GROUP_ID="PVD" ID="125707030513421999" MERGED_FROM="" MODIFIED="2013-05-28 12:19:02 +0100" MODIFIED_BY="Cathryn Broderick" REVIEW_NO="1251" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2013-05-28 12:19:02 +0100" MODIFIED_BY="Cathryn Broderick">
<TITLE>Ginkgo biloba for intermittent claudication</TITLE>
<CONTACT MODIFIED="2013-05-28 12:19:02 +0100" MODIFIED_BY="Cathryn Broderick"><PERSON ID="17950" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Joep</FIRST_NAME><MIDDLE_INITIALS>AW</MIDDLE_INITIALS><LAST_NAME>Teijink</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Vascular Surgeon</POSITION><EMAIL_1>joep.teijink@cze.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Catharina Hospital</ORGANISATION><CITY>Eindhoven</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 40 2398764</PHONE_1><FAX_1>+31 40 2443370</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-05-28 12:19:02 +0100" MODIFIED_BY="Cathryn Broderick"><PERSON ID="2207554F82E26AA201CB1278FE76D1E5" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Saskia</FIRST_NAME><MIDDLE_INITIALS>PA</MIDDLE_INITIALS><LAST_NAME>Nicolaï</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Researcher</POSITION><EMAIL_1>saskianicolai@gmail.com</EMAIL_1><EMAIL_2>exitpad@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>Maastricht University</ORGANISATION><CITY>Maastricht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 45 5767932</PHONE_1><FAX_1>+31 6 29392394</FAX_1></ADDRESS></PERSON><PERSON ID="2209E92982E26AA201CB12784B807708" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lotte</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Kruidenier</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Researcher</POSITION><EMAIL_1>l.kruidenier@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Catharina Hospital</ORGANISATION><CITY>Eindhoven</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 45 5767932</PHONE_1><FAX_1>+31 6 48048452</FAX_1></ADDRESS></PERSON><PERSON ID="17949" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bianca</FIRST_NAME><MIDDLE_INITIALS>LW</MIDDLE_INITIALS><LAST_NAME>Bendermacher</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>b.bendermacher@live.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Catharina Hospital</ORGANISATION><ADDRESS_1>Michelangelolaan 2</ADDRESS_1><CITY>Eindhoven</CITY><ZIP>5623 EJ</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 45 5766599</PHONE_1><FAX_1>+31 45 5766548</FAX_1></ADDRESS></PERSON><PERSON ID="15784" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Martin</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Prins</LAST_NAME><EMAIL_1>Mh.Prins@maastrichtuniversity.nl</EMAIL_1><EMAIL_2>mh.prins@maastrichtuniversity.nl</EMAIL_2><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>CAPHRI Research School, Maastricht University</ORGANISATION><CITY>Maastricht</CITY><ZIP>6200 MD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 43 3882901</PHONE_1><FAX_1>+31 43 3884128</FAX_1></ADDRESS></PERSON><PERSON ID="z1301301227513793614450285216298" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rutger</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Stokmans</LAST_NAME><EMAIL_1>rutger.stokmans@cze.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Catharina Hospital</ORGANISATION><CITY>Eindhoven</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="z1301301312509363463726578140695" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Pieter</FIRST_NAME><MIDDLE_INITIALS>PHL</MIDDLE_INITIALS><LAST_NAME>Broos</LAST_NAME><EMAIL_1>pieter.broos@catharinaziekenhuis.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Catharina Hospital</ORGANISATION><ADDRESS_1>PO Box 1350</ADDRESS_1><CITY>Eindhoven</CITY><ZIP>5602 ZA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>040 239 6349</PHONE_1><FAX_1>040 422 3370</FAX_1></ADDRESS></PERSON><PERSON ID="17950" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Joep</FIRST_NAME><MIDDLE_INITIALS>AW</MIDDLE_INITIALS><LAST_NAME>Teijink</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Vascular Surgeon</POSITION><EMAIL_1>joep.teijink@cze.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Catharina Hospital</ORGANISATION><CITY>Eindhoven</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 40 2398764</PHONE_1><FAX_1>+31 40 2443370</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-05-28 11:32:37 +0100" MODIFIED_BY="Cathryn Broderick">
<UP_TO_DATE>
<DATE DAY="13" MONTH="3" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="3" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="5" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-05-28 12:15:58 +0100" MODIFIED_BY="Heather  Maxwell">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-05-28 12:15:49 +0100" MODIFIED_BY="Cathryn  A Broderick">
<DATE DAY="13" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>Searches were rerun. No new studies were included. One new study was excluded. Minor copy edits made. Two authors added to review team. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-05-28 12:15:58 +0100" MODIFIED_BY="Cathryn  A Broderick">
<DATE DAY="13" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>Searches were rerun. No new studies were included. One new study was excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-02-10 13:07:01 +0000" MODIFIED_BY="Heather  Maxwell">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-10 13:07:01 +0000" MODIFIED_BY="Heather  Maxwell">
<DATE DAY="15" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-05-08 09:56:18 +0100" MODIFIED_BY="Heather  Maxwell">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2013-05-08 09:56:18 +0100" MODIFIED_BY="Heather  Maxwell">
<SOURCE MODIFIED="2013-05-08 09:56:18 +0100" MODIFIED_BY="Heather  Maxwell">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-05-28 11:46:28 +0100" MODIFIED_BY="Heather  Maxwell">
<SUMMARY MODIFIED="2013-05-07 13:38:25 +0100" MODIFIED_BY="Heather  Maxwell">
<TITLE MODIFIED="2008-09-23 12:40:10 +0100" MODIFIED_BY="Heather  Maxwell">
<I>Ginkgo biloba for people with leg pain while walking (intermittent claudication)</I>
</TITLE>
<SUMMARY_BODY MODIFIED="2013-05-07 13:38:25 +0100" MODIFIED_BY="Heather  Maxwell">
<P>The main symptom of peripheral arterial disease (PAD) is leg pain in one or both calves while walking. Typically, this pain occurs during walking and is relieved by a short period of rest. This clinical phenomenon is called intermittent claudication (IC). Peripheral arterial disease is caused by progressive narrowing of the arteries in one or both legs and is a manifestation of systematic atherosclerosis, possibly leading to cardiovascular events. Conservative treatment consists of treatment for cardiovascular risk factors and symptomatic relief by exercise therapy and pharmacological treatments. One of the pharmacotherapeutical options is Ginkgo biloba extract, which is derived from the leaves of the Ginkgo biloba tree and has been used in traditional Chinese medicine for centuries. It is a vasoactive agent which is believed to have a positive effect on walking ability in patients with PAD. This review shows that people using Ginkgo biloba could walk 64.5 metres further, which was a non-significant difference compared with the placebo group. Overall, there is no evidence that Ginkgo biloba has a clinically significant benefit for patients with PAD.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-05-09 10:44:04 +0100" MODIFIED_BY="Heather  Maxwell">
<ABS_BACKGROUND MODIFIED="2013-05-07 13:36:46 +0100" MODIFIED_BY="Heather  Maxwell">
<P>People with intermittent claudication (IC) suffer from pain in the muscles of the leg occurring during exercise which is relieved by a short period of rest. Symptomatic relief can be achieved by (supervised) exercise therapy and pharmacological treatments. Ginkgo biloba is a vasoactive agent and is used to treat IC.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-04-16 13:34:33 +0100" MODIFIED_BY="Heather  Maxwell">
<P>To assess the effect of Ginkgo biloba on walking distance in people with intermittent claudication.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-04-22 12:16:56 +0100" MODIFIED_BY="Heather  Maxwell">
<P>For this update<I> </I>the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (March 2013) and CENTRAL (2013, Issue 2).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-05-07 13:36:53 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Randomised controlled trials of Ginkgo biloba extract, irrespective of dosage, versus placebo in people with IC. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-07-18 14:57:29 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed trials for selection, assessed study quality and extracted data. We extracted number of patients, mean walking distances or times and standard deviations. To standardise walking distance or time, caloric expenditures were used to express the difference between the different treadmill protocols, which were calculated from the speed and incline of the treadmill.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-05-09 10:44:04 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Fourteen trials with a total of 739 participants were included. Eleven trials involving 477 participants compared Ginkgo biloba with placebo and assessed the absolute claudication distance (ACD). Following treatment with Ginkgo biloba at the end of the study the ACD increased with an overall effect size of 3.57 kilocalories (confidence interval (CI) -0.10 to 7.23, P = 0.06), compared with placebo. This translates to an increase of just 64.5 ( CI -1.8 to 130.7) metres on a flat treadmill with an average speed of 3.2 km/h. Publication bias leading to missing data or "negative" trials is likely to have inflated the effect size.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-04-16 13:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, there is no evidence that Ginkgo biloba has a clinically significant benefit for patients with peripheral arterial disease.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-05-28 11:45:49 +0100" MODIFIED_BY="Heather  Maxwell">
<BACKGROUND MODIFIED="2013-05-08 09:52:59 +0100" MODIFIED_BY="Heather  Maxwell">
<CONDITION MODIFIED="2013-05-08 09:52:59 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Patients with peripheral arterial disease (PAD) suffer from a progressive narrowing and hardening of the arteries in one or both legs (atherosclerosis). The most common symptom of PAD is intermittent claudication (IC) defined as pain in the muscles of the leg occurring during exercise which is relieved by a short period of rest. This clinical phenomenon affects 1.6% to 4.5% of all people in the general population (<LINK REF="REF-Fowkes-1991" TYPE="REFERENCE">Fowkes 1991</LINK>; <LINK REF="REF-Hooi-1998" TYPE="REFERENCE">Hooi 1998</LINK>; <LINK REF="REF-Meijer-1998" TYPE="REFERENCE">Meijer 1998</LINK>; <LINK REF="REF-Murabito-2002" TYPE="REFERENCE">Murabito 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-05-07 13:39:03 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Basic conservative treatment for patients with IC includes risk-factor modification and exercise therapy. Intermittent claudication is a manifestation of systemic atherosclerosis, thus all patients with this symptom should be treated with medical therapy for cardiovascular risk factors. Glucose and cholesterol metabolism and blood pressure should be optimised and, as smoking is considered the most important modifiable vascular risk factor, attention should be paid to smoking cessation. Antiplatelet therapy is indicated for all patients with IC to reduce the risk of a cardiovascular event (<LINK REF="REF-ATC-2002" TYPE="REFERENCE">ATC 2002</LINK>). Exercise therapy can improve the absolute claudication distance (ACD) by 150% (<LINK REF="REF-Leng-2004" TYPE="REFERENCE">Leng 2004</LINK>) and should be prescribed for symptom relief. A supervised exercise programme has more clinical benefits than an unsupervised exercise programme. A recent Cochrane review showed approximately a 150 metre difference in increased walking distance after three months in favour of supervised exercise therapy programmes compared with non-supervised therapy (<LINK REF="REF-Bendermacher-2006" TYPE="REFERENCE">Bendermacher 2006</LINK>). Pharmacological treatments reported to be associated with improvement of leg symptoms include cilostazol, pentoxifylline, naftidrofuryl, statins, angiotensin-converting enzyme inhibitors and Ginkgo biloba extract (<LINK REF="REF-Bendermacher-2005" TYPE="REFERENCE">Bendermacher 2005</LINK>; <LINK REF="REF-Hankey-2006" TYPE="REFERENCE">Hankey 2006</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-05-07 13:39:23 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Ginkgo biloba extract is derived from the leaves of Ginkgo biloba<I>, </I>the only surviving species of the Ginkgoaceae family of trees. It has been used in traditional Chinese medicine for centuries. In the western world Ginkgo biloba extract is prescribed mainly for IC, cerebral insufficiency and tinnitus. The extract is made from dried leaves, and preparations for use are standardised to contain the same ingredients in similar doses of 24% ginkgo flavonoids and 6% terpenoids. Flavonoids are believed to contribute to Ginkgo's antioxidant properties. In vitro studies of Ginkgo biloba demonstrated free-radical scavenging properties (<LINK REF="REF-Pincemail-1989" TYPE="REFERENCE">Pincemail 1989</LINK>) and prolongation of the half-life of endothelial-derived relaxing factor (<LINK REF="REF-Robak-1988" TYPE="REFERENCE">Robak 1988</LINK>) resulting in improved microcirculation by inducing relaxation of contracted blood vessels (<LINK REF="REF-Kleijnen-1992" TYPE="REFERENCE">Kleijnen 1992</LINK>). In other in vitro experiments, the ginkgolides, components of the terpenoids, inhibit the activity of platelet-activating factor (<LINK REF="REF-Korth-1988" TYPE="REFERENCE">Korth 1988</LINK>), resulting in diminished platelet aggregation, neutrophil degranulation and oxygen-free radical production (<LINK REF="REF-Kleijnen-1992" TYPE="REFERENCE">Kleijnen 1992</LINK>). Based on the use of Ginkgo biloba in traditional Chinese medicine and the vasoactive properties of Ginkgo biloba, Ginkgo biloba is being used in Western medicine for the relief of symptoms of PAD.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-04-15 08:01:52 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>To establish the clinical effect in patients with PAD we performed a systematic review. Possible problems with such a review of Ginkgo biloba extract is the potential for small unpublished studies, especially from relatively inexperienced and small research groups. Moreover, strong beliefs and financial interest could hamper the publication of negative trials. Hence, it is important to explore the possibility of publication bias in detail.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-02-10 12:46:04 +0000" MODIFIED_BY="Heather  Maxwell">
<P>To determine the effect of Ginkgo biloba extract on the walking capacity of people with intermittent claudication.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-05-08 09:53:03 +0100" MODIFIED_BY="Heather  Maxwell">
<SELECTION_CRITERIA MODIFIED="2013-05-08 09:53:03 +0100" MODIFIED_BY="Heather  Maxwell">
<CRIT_STUDIES MODIFIED="2013-05-07 13:40:55 +0100" MODIFIED_BY="Heather  Maxwell">
<P>All randomised controlled trials of Ginkgo biloba extract versus placebo in people with IC (stage II according to Fontaine (<LINK REF="REF-Fontaine-1954" TYPE="REFERENCE">Fontaine 1954</LINK>); stages 1 to 3 according to Rutherford (<LINK REF="REF-Rutherford-1997" TYPE="REFERENCE">Rutherford 1997</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-05-07 13:41:00 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Adults (18 years and older) with IC, according to Fontaine stage II or Rutherford stages 1 to 3.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-05-07 13:41:12 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Ginkgo biloba extract was compared with placebo for IC. Incuded studies used standardised Ginkgo biloba extracts. All studies were included irrespective of dosage.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-05-08 09:53:03 +0100" MODIFIED_BY="[Empty name]">
<P> </P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-03-20 11:32:35 +0000" MODIFIED_BY="Cathryn  A Broderick">
<P>The primary outcome measurement was the absolute claudication distance (ACD) at the end of the study.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-05-08 09:53:03 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Secondary outcomes were initial claudication distance (ICD), ankle brachial index (ABI), quality of life (QoL) and adverse reactions.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-04-22 12:08:28 +0100" MODIFIED_BY="Heather  Maxwell">
<ELECTRONIC_SEARCHES MODIFIED="2013-04-22 12:08:28 +0100" MODIFIED_BY="Heather  Maxwell">
<P>For this update<I> </I>the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (March 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 2, part of <I>The Cochrane Library</I>, (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A>) section of the Cochrane Peripheral Vascular Diseases Group module in <I>The Cochrane Library (</I>
<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>).</P>
<P>For the previous version of the review the authors searched MEDLINE/PUBMED (January 1966 to May 2008) and EMBASE (January 1985 to May 2008) using the search strategy described in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> which was adapted for each database.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-23 12:54:19 +0100" MODIFIED_BY="Heather  Maxwell">
<P>We checked the reference lists of all retrieved articles. In addition, we attempted to identify unpublished studies and contacted manufacturers of Ginkgo biloba products to ask for information about any published and unpublished studies. We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-04-22 12:00:18 +0100" MODIFIED_BY="Heather  Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">Selection of trials</HEADING>
<P>For the 2013 update, two authors (RS and PB) independently assessed trials identified by the literature search. In the previous version, two authors (SN and LK) independently selected eligible trials identified by the literature search.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of trials</HEADING>
<P>Two authors (SN and LK) independently assessed the selected trials for methodological quality using The Cochrane Collaboration tool for assessing risk of bias (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Trials were assessed with respect to sequence generation, allocation concealment and blinding in each group. We resolved discrepancies by discussion, or, if this failed, by consulting authors MP and JT. The results were checked for accuracy by BB.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two authors (SN and LK) independently extracted data using standardised data extraction forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>Data were analysed using Review Manager (RevMan 5) software. Treadmill testing is the main assessment used to quantify therapy effect and walking ability in patients with PAD. In studies concerning medical therapy for PAD, the change in walking distance is assessed by different treadmill protocols that vary in speed and incline of the treadmill. Owing to the diverse workloads of different protocols, it is difficult to compare increases in walking distance (metres) or time. To standardise walking distance caloric expenditure is used to express the difference. This was calculated from the speed and incline of the treadmill.</P>
<P>We explored publication bias by relating the observed treatment effect  to the standard error of the mean difference. We used meta-regression to assess statistically the effect of publication bias. For this purpose the square root of the size of the study was introduced as a covariate in the assessment of the size of the treatment effect. Three domains of quality assessment were applied according to The Cochrane Collaboration tool for assessing risk of bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). As many studies were assessed as unclear risk of bias, all studies were included in the primary analysis (see Risk of Bias section). Additionally, we explored dose-effect relationship using meta-regression.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-05-28 11:39:51 +0100" MODIFIED_BY="Heather  Maxwell">
<STUDY_DESCRIPTION MODIFIED="2013-05-28 11:39:51 +0100" MODIFIED_BY="Heather  Maxwell">
<SEARCH_RESULTS MODIFIED="2013-04-24 13:10:19 +0100" MODIFIED_BY="Heather  Maxwell">
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>No additional studies were identified for inclusion in this update. One additional study was excluded (<LINK REF="STD-Sandreau-1989" TYPE="STUDY">Sandreau 1989</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-05-28 11:39:51 +0100" MODIFIED_BY="Heather  Maxwell">
<P>For details of included studies <I>see </I>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>We included 14 randomised controlled trials; 11 published trials and three unpublished trials. Five of the published articles were published in German (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Blume-1998" TYPE="STUDY">Blume 1998</LINK>; <LINK REF="STD-Bulling-1991" TYPE="STUDY">Bulling 1991</LINK>; <LINK REF="STD-Salz-1980" TYPE="STUDY">Salz 1980</LINK>); five in English (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>; <LINK REF="STD-Peters-1998" TYPE="STUDY">Peters 1998</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>; <LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>); and one in Danish (<LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>). One clinical trial was published as an abstract (<LINK REF="STD-Schoop-1997" TYPE="STUDY">Schoop 1997</LINK>). Two internal reports with unpublished data (<LINK REF="STD-Diehm-1990" TYPE="STUDY">Diehm 1990</LINK>; <LINK REF="STD-Natali-1985" TYPE="STUDY">Natali 1985</LINK>) which were mentioned in other published meta-analyses (<LINK REF="REF-Horsch-2004" TYPE="REFERENCE">Horsch 2004</LINK>; <LINK REF="REF-Letzel-1992" TYPE="REFERENCE">Letzel 1992</LINK>; <LINK REF="REF-Pittler-2000" TYPE="REFERENCE">Pittler 2000</LINK>; <LINK REF="REF-Schneider-1992" TYPE="REFERENCE">Schneider 1992</LINK>) were requested from the manufacturers. We contacted all authors of trials who did not report means and standard deviation for walking distances. However, we only received additional data for one trial (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>). The two most recent trials were published in 2007 and 2008 (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>). The remaining 12 trials were published between 1984 and 1998.</P>
<P>The fourteen included trials involved a total of 739 participants. All these studies compared Ginkgo biloba with placebo in people with IC. The trials were conducted in Germany (8), France (2), Denmark (1), United States of America (1), United Kingdom (1) and Australia (1).The number of participants included in each trial varied between 18 and 209. The majority of trials included less than 50 participants and only two trials included more than 100 patients (<LINK REF="STD-Peters-1998" TYPE="STUDY">Peters 1998</LINK>; <LINK REF="STD-Schoop-1997" TYPE="STUDY">Schoop 1997</LINK>). The mean age of the participants in the included trials varied between 60.9 and 71.6 years. Eleven trials included male and female participants. In three trials the gender of the participants was not described (<LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>; <LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>).</P>
<P>In one trial maximal trained participants who did not further improve after a walking program of three to four times per week were included (<LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>). In another trial all participants received exercise therapy in combination with participation in the study (<LINK REF="STD-Bulling-1991" TYPE="STUDY">Bulling 1991</LINK>), and one trial offered exercise therapy to all patients (<LINK REF="STD-Peters-1998" TYPE="STUDY">Peters 1998</LINK>). In this trial no information was given regarding how many patients actually participated in the exercise training program.</P>
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>In all 14 trials the patients had PAD according to Fontaine stage II (<LINK REF="REF-Fontaine-1954" TYPE="REFERENCE">Fontaine 1954</LINK>). Six trials mentioned that the situation should have been stable for a given period (three months to one year) (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Blume-1998" TYPE="STUDY">Blume 1998</LINK>; <LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>; <LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>; <LINK REF="STD-Natali-1985" TYPE="STUDY">Natali 1985</LINK>; <LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>), and in three trials the diagnosis was confirmed by angiography (<LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Blume-1998" TYPE="STUDY">Blume 1998</LINK>; <LINK REF="STD-Peters-1998" TYPE="STUDY">Peters 1998</LINK>). Four trials applied an age restriction; 40 to 75 years (<LINK REF="STD-Diehm-1990" TYPE="STUDY">Diehm 1990</LINK>); 35 to 75 years (<LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>); 30 to 75 years (<LINK REF="STD-Natali-1985" TYPE="STUDY">Natali 1985</LINK>); and 50 to 80 years (<LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>). In nine studies an upper limit of the ACD or ICD was used as an inclusion criterion. Inclusion criterion for the ACD were an ACD &lt; 300 metres (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>), ACD between 50 and 500 metres (<LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>; <LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>) or an ACD between 100 and 500 metres (<LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>) as assessed by treadmill testing. Inclusion criteria for the ICD were an ICD &lt; 150 metres (<LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Peters-1998" TYPE="STUDY">Peters 1998</LINK>), ICD &lt; 300 metres (<LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>) or an ICD between 50 and 200 metres (<LINK REF="STD-Bulling-1991" TYPE="STUDY">Bulling 1991</LINK>; <LINK REF="STD-Diehm-1990" TYPE="STUDY">Diehm 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>The exclusion criteria were slightly variable between trials (<I>see</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). In all studies patients with PAD according to Fontaine stage III or IV were excluded. Patients with other reasons for a limited walking distance, e.g. cardiopulmonary or orthopaedic co-morbidities were also excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dosage and duration of treatment</HEADING>
<P>There were no dose-related restrictions to the included trials in this review. Six trials included a comparison of 120 mg Ginkgo biloba daily versus placebo (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Diehm-1990" TYPE="STUDY">Diehm 1990</LINK>; <LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>; <LINK REF="STD-Peters-1998" TYPE="STUDY">Peters 1998</LINK>; <LINK REF="STD-Schoop-1997" TYPE="STUDY">Schoop 1997</LINK>) and three trials included the comparison of 160 mg Ginkgo biloba daily versus placebo (<LINK REF="STD-Blume-1998" TYPE="STUDY">Blume 1998</LINK>; <LINK REF="STD-Natali-1985" TYPE="STUDY">Natali 1985</LINK>; <LINK REF="STD-Salz-1980" TYPE="STUDY">Salz 1980</LINK>). Three trials, including the two most recent ones, compared daily dosages of 240 mg (<LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>), 300 mg (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>) and 320 mg (<LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>) Ginkgo biloba extract with placebo. The maximal follow-up period of eight trials was 24 weeks, of one trial 16 weeks, of three trials 12 weeks, of one trial six weeks, and of one trial four weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome measurements</HEADING>
<P>The primary outcome measurement of the study was ACD. In 13 trials walking distances were mentioned. Data on the walking distances could not be retrieved from one trial (<LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>). In two other studies, only data from ICD were presented (<LINK REF="STD-Schoop-1997" TYPE="STUDY">Schoop 1997</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>). In 12 trials treadmill testing with different protocols was used to assess the ACD and/or ICD. In one trial (<LINK REF="STD-Salz-1980" TYPE="STUDY">Salz 1980</LINK>) walking distance was measured by walking on a flat floor with two steps per second.</P>
<P>In six trials data from ankle brachial index (ABI) or ankle pressures were presented (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Bulling-1991" TYPE="STUDY">Bulling 1991</LINK>; <LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>; <LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>; <LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>).Only one study reported quality of life as administered by the MOS SF-36 questionnaire (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>). Four trials presented data of a Visual Analogue Scale (VAS-scale) for the subjective estimate of pain (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>) and one trial presents a VAS-scale for functional impairment (<LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>). Nine trials reported on tolerance and adverse reactions of the medication and the placebo (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Blume-1998" TYPE="STUDY">Blume 1998</LINK>; <LINK REF="STD-Bulling-1991" TYPE="STUDY">Bulling 1991</LINK>; <LINK REF="STD-Diehm-1990" TYPE="STUDY">Diehm 1990</LINK>; <LINK REF="STD-Natali-1985" TYPE="STUDY">Natali 1985</LINK>; <LINK REF="STD-Peters-1998" TYPE="STUDY">Peters 1998</LINK>; <LINK REF="STD-Schoop-1997" TYPE="STUDY">Schoop 1997</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-05-08 09:53:07 +0100" MODIFIED_BY="Heather  Maxwell">
<P>For this update one additional study (<LINK REF="STD-Sandreau-1989" TYPE="STUDY">Sandreau 1989</LINK>) was excluded because it only included patients diagnosed with PAD stage III according to Fontaine. Twelve randomised controlled trials were excluded from analysis in 2009. Five of these trials compared Ginkgo biloba with another pharmacological treatment; dextran (<LINK REF="STD-Baitsch-1986" TYPE="STUDY">Baitsch 1986</LINK>), buflomedil (<LINK REF="STD-Berndt-1987" TYPE="STUDY">Berndt 1987</LINK>), pentoxifylline (<LINK REF="STD-Bohmer-1988" TYPE="STUDY">Bohmer 1988</LINK>), naftidrofuryl (<LINK REF="STD-Horsch-1998" TYPE="STUDY">Horsch 1998</LINK>), and the combination of Ginkgo biloba extract with magnesium and Levo-arginine compared with acetylsalicylic acid (<LINK REF="STD-Michelini-1998" TYPE="STUDY">Michelini 1998</LINK>). In four trials, conducted in 1975, 1977 and 1981, the inclusion criterion to include patients only with PAD stage II according to Fontaine was not met and separate data for patients diagnosed with PAD stage II according to Fontaine were not available (<LINK REF="STD-Ambrosi-1975" TYPE="STUDY">Ambrosi 1975</LINK>; <LINK REF="STD-Courbier-1977" TYPE="STUDY">Courbier 1977</LINK>; <LINK REF="STD-Frileux-1975" TYPE="STUDY">Frileux 1975</LINK>; <LINK REF="STD-Garzya-1981" TYPE="STUDY">Garzya 1981</LINK>). In one trial the primary aim was to compare diabetic and non-diabetic PAD patients (<LINK REF="STD-Li-1998" TYPE="STUDY">Li 1998</LINK>) and one double blind randomised cross-over study evaluated the short term effect (within 60 minutes) of Ginkgo biloba extract versus placebo in patients with PAD stage II according to Fontaine (<LINK REF="STD-Rudofsky-1987" TYPE="STUDY">Rudofsky 1987</LINK>). One study compared two dosages of Ginkgo biloba extract without a placebo group (<LINK REF="STD-Schweizer-1999" TYPE="STUDY">Schweizer 1999</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-02-10 12:50:11 +0000" MODIFIED_BY="Heather  Maxwell">
<ALLOCATION MODIFIED="2009-02-09 15:41:11 +0000" MODIFIED_BY="Heather  Maxwell">
<P>All 14 trials were randomised trials, however explicit generation of the allocation sequence was only described in six trials (<LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Diehm-1990" TYPE="STUDY">Diehm 1990</LINK>; <LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>; <LINK REF="STD-Salz-1980" TYPE="STUDY">Salz 1980</LINK>; <LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>) where a random number generator was used.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-02-10 12:50:11 +0000" MODIFIED_BY="Heather  Maxwell">
<P>Only one trial explicitly described an adequate allocation concealment. In this trial the allocation sequence was administered by a third party who was not involved in the study (<LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>). All trials were reported to be double blinded. However, only three trials describe explicitly how this blinding was performed and stated that participants and trial personnel were blinded to treatment assignment until the end of the study (<LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>). Because most of the studies were assessed as unclear risk of bias, all studies were included in the primary analysis (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</BLINDING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-05-09 10:44:45 +0100" MODIFIED_BY="Heather  Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">Absolute claudication distance</HEADING>
<P>Data for the ACD at the end of the study were available in 11 trials with a total sample size of 477 participants. The effect was calculated after standardisation of the presented walking distances. The total caloric expenditure was calculated from the speed and incline of the treadmill and if possible the weight of the participants. At the end of the study the ACD increased with an overall effect size of 3.57 kcal (confidence interval (CI) -0.10 to 7.23, P = 0.06) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), in favour of the Ginkgo biloba group, using a random-effects model. For a 70 kg weighted person this can be translated to an increase of 64.5 metres (CI -1.8 to 130.7) on a flat treadmill with an average speed of 3.2 km/h, which is most comparable with walking in daily life. </P>
<P>Furthermore, the effect size was calculated for 24 weeks of treatment (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), 12 to 16 weeks of treatment (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) and 6 to 8 weeks of treatment (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) with Ginkgo biloba extract versus placebo. After a follow-up period of 24 weeks, data for six trials for ACD were available with a sample size of 321 participants. The ACD was increased with an overall effect size of 4.72 kcal (CI 2.27 to 7.16, P = 0.0002), in favour of the Ginkgo biloba group, using a random-effects model. This can be translated to 85.3 metres (CI 41.0 to 129.4) on a flat treadmill with an average speed of 3.2 km/h. After 12 to 16 weeks of follow-up data of eight trials (n = 339) present an increase in ACD with an overall effect size of 1.36 kcal (CI -2.63 to 5.36, P = 0.50). This was comparable with the overall effect size of 2.19 kcal ( CI -0.62 to 4.99, P = 0.13) after 6 to 8 weeks of follow up (n = 236).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Initial claudication distance</HEADING>
<P>Data for the ICD were present in 13 trials at the end of the study within a total of 723 participants (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). The ICD increased with a overall effect size of 1.84 kcal (CI -0.92 to 4.61, P = 0.19) with a random-effects model in favour of the Ginkgo biloba group. This corresponds with an increase in 33.3 metres (CI -16.7 to 83.3) for a 70 kg weighted adult with 3.2 km/h on a flat treadmill. After 24 weeks of treatment the overall effect size was 2.15 kcal (CI -2.06 to 6.36, P = 0.32) in favour of the Ginkgo biloba group (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). After 12 to 16 weeks (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>) and 6 to 8 weeks (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>) the overall effect sizes were 1.54 kcal (CI -0.04 to 3.12, P = 0.06) and 2.72 kcal (CI 0.75 to 4.69, P = 0.007), respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ankle brachial index</HEADING>
<P>In three trials the ABI (<LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>; <LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>) and in three trials ankle pressures (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Bulling-1991" TYPE="STUDY">Bulling 1991</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>) were presented. Therefore, the standardised mean differences were used to show an overall effect size of -0.22 (CI &#8211;0.58 to 0.15, P = 0.25) on the ABI or ankle pressures in favour of the placebo group (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>One study collected QoL data using the standardised MOS SF-36 questionnaire (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>). This study showed a significant improvement for the &#8220;role physical&#8221; domain in favour of the Ginkgo biloba study group (P = 0.03). The subjective assessment of pain and functional impairment administered by a VAS scale increased with an overall effect of 0.38 (CI &#8211;0.94 to 1.70, P = 0.57) in the Ginkgo biloba group (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>; <LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>) (<LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse reactions</HEADING>
<P>Most common side effects of Ginkgo biloba included gastro-intestinal complaints, headache, allergic skin reactions. Furthermore, Ginkgo biloba may increase the risk of bleeding. Nine out of 14 studies reported tolerance on Ginkgo biloba, as assessed by adverse reactions. In five trials no side effects were observed (<LINK REF="STD-Blume-1998" TYPE="STUDY">Blume 1998</LINK>; <LINK REF="STD-Bulling-1991" TYPE="STUDY">Bulling 1991</LINK>; <LINK REF="STD-Diehm-1990" TYPE="STUDY">Diehm 1990</LINK>; <LINK REF="STD-Peters-1998" TYPE="STUDY">Peters 1998</LINK>; <LINK REF="STD-Schoop-1997" TYPE="STUDY">Schoop 1997</LINK>). In the other four trials the following side effects were reported; nausea (2), gastro-intestinal complaints (2), blood in the urine (1), headache (1) (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Natali-1985" TYPE="STUDY">Natali 1985</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>). Overall, a low percentage of adverse reactions, which were all minor side effects, were found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of publication bias</HEADING>
<P>To explore publication bias two funnel plots in which the standard error of the mean difference was plotted against the mean difference were performed. The funnel plots for the ACD at the end of the study and the ACD after 24 weeks of follow up suggested publication bias as many smaller studies had more positive results. (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>; <LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dosage of Ginkgo biloba</HEADING>
<P>Meta-regression analysis did not show a significant effect on the effect of Ginkgo biloba on walking distance; neither did the dosage of the Ginkgo biloba extract.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-05-09 10:45:14 +0100" MODIFIED_BY="Heather  Maxwell">
<SUMMARY_OF_RESULTS MODIFIED="2013-05-09 10:45:14 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Eleven included trials with a total sample size of 477 patients did reveal non significant increases in ACD at the end of the study with a total effect size of 3.57 kcal. This corresponds with an increase of 64.5 metres on a flat treadmill (average speed 3.2 km/h). However, in clinical studies, most frequently a treadmill protocol of 3.2 km/h and 10% incline is used to assess therapy effect. Applying this protocol, 3.57 kcal represents an increase of 31 metres.<B> </B>
</P>
<P>After 24 weeks of treatment we found a significant improvement in ACD with an overall effect size of 4.72 kcal, corresponding with 85.3 metres. However, in this analysis the number of patients who contributed was smaller, n = 321, and this analysis is likely to be more prone to publication bias (<LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>).</P>
<P>For comparison, exercise therapy which is the main conservative treatment for symptomatic relief, is associated with 150% overall improvement of the ACD (<LINK REF="REF-Leng-2004" TYPE="REFERENCE">Leng 2004</LINK>). This translates into a benefit of 19.1 to 39.9 kcal, depending on the applied treadmill protocol to assess the improvement in walking distance. (19.1 kcal for 3.2 km/h and 0% increase, 39.9 kcal for 3.2 km/h and 10%, energy expenditures of graded protocols lie in between both). Hence, the effect of exercise therapy can be estimated to be approximately 5 to10 times greater than that of Ginkgo biloba extract. Moreover, supervised exercise therapy programs have an additional and significantly greater benefit than non-supervised regimens (<LINK REF="REF-Bendermacher-2006" TYPE="REFERENCE">Bendermacher 2006</LINK>).</P>
<P>Other meta-analyses comparing pharmacological therapy (cilostazol, buflomedil, pentoxifylline and naftidrofuryl) with placebo for IC show similar results (<LINK REF="REF-Robless-2008" TYPE="REFERENCE">Robless 2008</LINK>; <LINK REF="REF-de-Backer-2008" TYPE="REFERENCE">de Backer 2008</LINK>; <LINK REF="REF-de-Backer-2008a" TYPE="REFERENCE">de Backer 2008a</LINK>; <LINK REF="REF-Girolami-1999" TYPE="REFERENCE">Girolami 1999</LINK>; <LINK REF="REF-Moher-2000" TYPE="REFERENCE">Moher 2000</LINK>). Possibly, the results on walking distance for buflomedil are most conclusive. Although all these comparisons are indirect, they support the generally accepted view that (supervised) exercise therapy is the main conservative therapy for patients with IC.</P>
<SUBSECTION>
<HEADING LEVEL="2">Clinical relevance</HEADING>
<P>The clinical relevance of a non significant improvement of 64.5 metres in ACD is questionable. Quality of life, which is probably more important than the regained walking distance (for the patients' well being), was evaluated in only one trial. In this single study there was a borderline significant improvement of QoL (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>). However, five trials assessed subjective assessment of pain and functional impairment by a VAS scale, which failed to show a statistically significant effect (<LINK REF="STD-Bauer-1984" TYPE="STUDY">Bauer 1984</LINK>; <LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>; <LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Limitations of this review</HEADING>
<P>Eleven out of fourteen studies reported data on ACD. Authors of the three other studies were contacted for the walking distances. However, they did not respond (<LINK REF="STD-Mouren-1994" TYPE="STUDY">Mouren 1994</LINK>; <LINK REF="STD-Schoop-1997" TYPE="STUDY">Schoop 1997</LINK>; <LINK REF="STD-Thomson-1990" TYPE="STUDY">Thomson 1990</LINK>). In two articles only the median was presented with the corresponding 95% confidence intervals (CI) (<LINK REF="STD-Blume-1996" TYPE="STUDY">Blume 1996</LINK>; <LINK REF="STD-Drabaek-1996" TYPE="STUDY">Drabaek 1996</LINK>). The authors were contacted but did not reply and the median was used instead of the mean and the standard deviation was calculated from the 95% CI. In one study the standard deviations were not directly available and had to be derived from the reported P values (<LINK REF="STD-Blume-1998" TYPE="STUDY">Blume 1998</LINK>). Unfortunately, in two studies only the differences to the ACD at the start of the study were available with the corresponding P values. The ACD at baseline was calculated with the known proportions of the ICD and ACD in the other included studies (<LINK REF="STD-Peters-1998" TYPE="STUDY">Peters 1998</LINK>; <LINK REF="STD-Salz-1980" TYPE="STUDY">Salz 1980</LINK>).</P>
<P>
<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK> and <LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK> suggested publication bias as many smaller studies had more positive results. This publication bias leading to missing data or "negative" trials is likely to have inflated the effect size. Furthermore, most included studies were performed with a small sample size; the majority included less than 50 participants. Special attention should be paid for a more recent study by Wang et al. (<LINK REF="STD-Wang-2007" TYPE="STUDY">Wang 2007</LINK>) that presented data of 17 participants and is the only study that reported results contrary to the other studies (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-05-28 11:45:49 +0100" MODIFIED_BY="Heather  Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2013-05-28 11:45:49 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Ginkgo biloba has no significant effect on walking distance in people with IC. Even if the small positive point estimate of the effect could be documented to be statistically significant in a larger trial, this effect would be marginal to the effect of (supervised) exercise therapy. Hence, currently no evidence supports the use of Ginkgo biloba in the treatment of PAD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-08-21 10:17:39 +0100" MODIFIED_BY="[Empty name]">
<P>Before Ginkgo biloba can be advised for the use in clinical practice further research would be required. However, given the small absolute summary effect in the reported trials, it is unlikely that the effect of Ginkgo biloba will ever be clinically relevant.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-09-09 08:25:17 +0100" MODIFIED_BY="[Empty name]">
<P>None</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-05-28 11:46:28 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>MP reports his institution has received funds for his Board membership of clinical studies and invited speaker activities from Bayer, Pfizer, Leo, Daichi Sankyo and Sanofi-Aventis. These were not related to this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-05-07 13:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>Saskia Nicolaï and Lotte Kruidenier independently selected trials for inclusion, assessed study quality and extracted data. Bianca Bendermacher checked all results for accuracy. Martin Prins and Joep Teijink resolved disagreements. For the 2013 update, Rutger Stokmans and Pieter Broos independently selected trials for inclusion.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-05-28 11:54:24 +0100" MODIFIED_BY="Heather  Maxwell">
<STUDIES MODIFIED="2013-05-28 11:54:24 +0100" MODIFIED_BY="Heather  Maxwell">
<INCLUDED_STUDIES MODIFIED="2013-05-28 11:54:24 +0100" MODIFIED_BY="Heather  Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Bauer-1984" MODIFIED="2013-05-06 09:59:15 +0100" MODIFIED_BY="[Empty name]" NAME="Bauer 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-05-06 09:59:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauer U</AU>
<TI>6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency</TI>
<SO>Arzneimittelforschung</SO>
<YR>1984</YR>
<VL>34</VL>
<NO>6</NO>
<PG>716-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blume-1996" MODIFIED="2009-02-09 14:56:15 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Blume 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-02-09 14:56:15 +0000" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blume J, Kieser M, Holscher U</AU>
<TI>[Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication]</TI>
<SO>Vasa</SO>
<YR>1996</YR>
<VL>25</VL>
<NO>3</NO>
<PG>265-74</PG>
<IDENTIFIERS MODIFIED="2009-02-09 14:56:15 +0000" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blume-1998" MODIFIED="2008-09-23 12:18:09 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Blume 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-23 12:18:09 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blume J, Kieser M, Hölscher U</AU>
<TI>Ginkgo-special-extract EGb 761 in peripheral arterial occlusive diseases stage IIb according to Fontaine</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1998</YR>
<VL>116</VL>
<NO>35-6</NO>
<PG>36-7</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:10:24 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bulling-1991" MODIFIED="2013-05-06 10:03:42 +0100" MODIFIED_BY="[Empty name]" NAME="Bulling 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-05-06 10:03:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bulling B, von Bary S</AU>
<TI>Treatment of chronic peripheral occlusive disease with physical training and ginkgo biloba extract 761</TI>
<TO>Behandlung der chronischen peripheren arteriellen Verschlusskrankheit met physikalischem Training und Ginkgo-biloba-Extrakt 761, Ergebnisse einer placebokontrollierten Doppelblindstudie</TO>
<SO>Medizinische Welt</SO>
<YR>1991</YR>
<VL>42</VL>
<NO>8</NO>
<PG>702-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Diehm-1990" MODIFIED="2008-09-23 12:02:04 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Diehm 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-09-23 12:02:04 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Diehm C, Heinrich F, Mörl H</AU>
<TI>Placebo-controlled, multicentre, randomised, double-blind pilot study examining the effectiveness of Ginkgo biloba extract EGb 761® in patients with Fontaine stage IIb peripheral aterial disease</TI>
<TO>Placebokontrollierte, multizentrische, randomisierte, doppelblinde Pilotstudie zur Prüfung der Wirksamkeit des Ginkgo-biloba-Extraktes EGb 761® bei Patienten mit peripherer arterieller Verschlusskrankheit im Stadium IIb nach Fontaine</TO>
<SO>Internal report. Dr. Willmar Schwabe GmbH &amp; Co.</SO>
<YR>1990</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drabaek-1996" MODIFIED="2013-05-06 10:06:34 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Drabaek 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-05-06 10:06:34 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drabaek H, Petersen JR, Winberg N, Hansen KF, Mehlsen J</AU>
<TI>The effect of Ginkgo biloba extract in patients with intermittent claudication</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1996</YR>
<VL>158</VL>
<NO>27</NO>
<PG>3928-31</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:10:47 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gardner-2008" MODIFIED="2013-05-06 10:09:17 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Gardner 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-06 10:09:17 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gardner CD, Taylor-Piliae RE, Kiazand A, Nicholus J, Rigby AJ, Farquhar JW</AU>
<TI>Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral arterial disease: a randomized clinical trial</TI>
<SO>Journal of Cardiopulmonary Rehabilitation and Prevention</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>4</NO>
<PG>258-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mouren-1994" MODIFIED="2008-09-23 12:12:10 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Mouren 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-23 12:12:10 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mouren X, Caillard P, Schwartz F</AU>
<TI>Study of the antiischemic action of EGb 761 in the treatment of peripheral arterial occlusive disease by TcPO2 determination</TI>
<SO>Angiology</SO>
<YR>1994</YR>
<VL>45</VL>
<NO>6</NO>
<PG>413-7</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:12:10 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Natali-1985" MODIFIED="2008-09-23 11:57:22 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Natali 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-09-23 11:57:22 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Natali J</AU>
<TI>Protocol for a study comparing Ginkgo biloba extract and placebo in patients with arteriopathy of the lower extremities</TI>
<TO>Protocole d'étude de l'extrait de Ginkgo biloba face au placebo dans l'artéropathie des membres inférieurs</TO>
<SO>Internal Study Report, Ipsen, Paris</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1998" MODIFIED="2008-09-23 12:12:54 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Peters 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-23 12:12:54 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters H, Kieser M, Holscher U</AU>
<TI>Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial</TI>
<SO>Vasa</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>2</NO>
<PG>106-10</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:12:54 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salz-1980" MODIFIED="2013-05-28 11:54:24 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Salz 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-05-28 11:54:24 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salz H</AU>
<TI>The effectiveness of a Ginkgo biloba preparation in arterial ischemic diseases of the leg. Controlled double-blind cross-over study</TI>
<SO>Therapie der Gegenwart</SO>
<YR>1980</YR>
<VL>119</VL>
<NO>11</NO>
<PG>1345-56</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:13:04 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoop-1997" MODIFIED="2013-05-06 10:16:51 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Schoop 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-05-06 10:16:51 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoop W, Breddin K, Diehm C, Grub J, Held K, Horsch S, et al</AU>
<TI>Clinical test with ginkgo biloba EGb 761 extract for patients with peripheral arterial occlusive disease stage IIb fontaine in comparison with placebo</TI>
<TO>Klinische prufung mit ginkgo biloba-spezialextrakt EGb 761 bei patienten mit peripherer arterieller verschlusskrankheit im stadium IIb nach fontaine im vergleich zu placebo</TO>
<SO>Vasa</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>160</NO>
<PG>P15</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:17:17 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomson-1990" MODIFIED="2013-05-06 10:18:49 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Thomson 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-05-06 10:18:49 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomson GJL, Vohra RK, Carr MH, Walker MG</AU>
<TI>A clinical trial of gingko biloba extract in patients with intermittent claudication</TI>
<SO>International Angiology</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>2</NO>
<PG>75-8</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:19:17 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007" MODIFIED="2013-05-06 10:20:21 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Wang 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-05-06 10:20:21 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Zhou S, Bronks R, Graham J, Myers S</AU>
<TI>Supervised exercise training combined with ginkgo biloba treatment for patients with peripheral arterial disease</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>7</NO>
<PG>579-86</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:19:39 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-05-08 09:44:44 +0100" MODIFIED_BY="Heather  Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Ambrosi-1975" MODIFIED="2013-05-08 09:44:14 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Ambrosi 1975" YEAR="1975">
<REFERENCE MODIFIED="2013-05-08 09:44:14 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ambrosi C, Bourde C</AU>
<TI>A new therapeutic intervention arteriopathies of the lower extremities: Tanakan. Clinical trial and study of liquid crystals</TI>
<TO>Nouveauté thèrapeutique médicinale dans les artériopathies des membres d'inferieur: Tanakan. Essai clinique et étude par les cristaux liquides</TO>
<SO>Gazette médicale de France</SO>
<YR>1975</YR>
<VL>82</VL>
<NO>6</NO>
<PG>628-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baitsch-1986" MODIFIED="2013-05-07 08:00:58 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Baitsch 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-05-07 08:00:58 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baitsch G</AU>
<TI>Treatment of obliterative arterial disease in diabetics Fontaine's stage IV with moist gangrene, an open randomized trial of Ginkgo-biloba extract Roekan vs. Dextran 40</TI>
<SO>Clinical Trials Journal</SO>
<YR>1986</YR>
<VL>23</VL>
<NO>1</NO>
<PG>11-9</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:21:51 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berndt-1987" MODIFIED="2013-05-08 09:44:44 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Berndt 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-05-08 09:44:44 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berndt ED, Kramer M</AU>
<TI>Medicational therapy of peripheral arterial occlusive disease in stage IIb</TI>
<TO>Medikamentöse Therapie der peripheren arteriellen Verschlusskrankheit im Staium IIb</TO>
<SO>die Therapiewoche</SO>
<YR>1986</YR>
<VL>37</VL>
<PG>2815-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohmer-1988" MODIFIED="2008-09-23 12:23:16 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Bohmer 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-09-23 12:23:16 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohmer D, Kalinski S, Michaelis P, Szogy A</AU>
<TI>Efficacy and tolerance of Ginkgo biloba extract compared to that of pentoxifylline in the treatment of patients suffering from peripheral chronic arterial occlusive disease</TI>
<SO>Hers Kreislauf</SO>
<YR>1988</YR>
<VL>20</VL>
<NO>1</NO>
<PG>5-8</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:23:16 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Courbier-1977" MODIFIED="2008-09-23 12:06:34 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Courbier 1977" YEAR="1977">
<REFERENCE MODIFIED="2008-09-23 12:06:34 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Courbier R, Jausseran JM, Reggi M</AU>
<TI>Double blind, cross over trial of Tanakan in arteriopathies of the lower extremities</TI>
<TO>Étude à double insu croisée du Tanakan dans les arteriopathies des membres inférieurs</TO>
<SO>Méditerranée Médicale</SO>
<YR>1977</YR>
<VL>126</VL>
<PG>61-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frileux-1975" MODIFIED="2013-05-07 08:10:00 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Frileux 1975" YEAR="1975">
<REFERENCE MODIFIED="2013-05-07 08:10:00 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frileux C, Cop R</AU>
<TI>Concentrated extract of Ginkgo biloba in peripheral vascular disorders</TI>
<TO>L'extrait concentré de Ginkgo biloba* dans les troubles vasculaires périphériques</TO>
<SO>Cahiers d'Artériologie de Royat</SO>
<YR>1975</YR>
<VL>3</VL>
<PG>117-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garzya-1981" MODIFIED="2013-05-07 08:15:31 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Garzya 1981" YEAR="1981">
<REFERENCE MODIFIED="2013-05-07 08:15:31 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garzya G, Picari M.</AU>
<TI>Treatment of peripheral vasculopathies with Ginkgo biloba extract</TI>
<TO>Trattamento della vasculopatie periferiche con una nuova sostanza estrattiva: il Tanakan</TO>
<SO>Clinica Europea</SO>
<YR>1981</YR>
<VL>20</VL>
<NO>5</NO>
<PG>936-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horsch-1998" MODIFIED="2008-09-23 12:24:32 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Horsch 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-23 12:24:32 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horsch S, Holscher U</AU>
<TI>Infusion therapy with ginkgo biloba special extract EGb 761 in patients with PAOD fontaine stages III and IV - A reference- controlled double-blind clinical trial</TI>
<SO>Munchener Medizinische Wochenschrift</SO>
<YR>1998</YR>
<VL>140</VL>
<NO>16</NO>
<PG>232-6</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:24:32 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1998" MODIFIED="2008-09-23 12:24:52 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Li 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-23 12:24:52 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li AL, Shi YD, Landsmann B, Schanowski-Bouvier P, Dikta G, Bauer U, et al</AU>
<TI>Hemorheology and walking of peripheral arterial occlusive diseases patients during treatment with Ginkgo biloba extract</TI>
<SO>Acta pharmacologica Sinica</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>5</NO>
<PG>417-21</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:24:52 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michelini-1998" MODIFIED="2013-05-07 08:19:44 +0100" MODIFIED_BY="[Empty name]" NAME="Michelini 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-05-07 08:19:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michelini S, Micci A, Failla A, Moneta G, Ottaviani A</AU>
<TI>Study on the efficacy of ginkgo biloba extract, magnesium and levo-arginine in the treatment of patients with 2<SUP>d</SUP> stage arteriopathies. A preliminary study</TI>
<TO>Studio sull'efficiaca dell'estratto di ginkgo biloba, magnesio e levo-arginina nel trattamento dei pazienti arteriopatici al II stadio</TO>
<SO>Minerva Cardioangiologica</SO>
<YR>1998</YR>
<VL>46</VL>
<NO>9</NO>
<PG>319-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudofsky-1987" MODIFIED="2008-09-23 12:25:33 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Rudofsky 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-09-23 12:25:33 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudofsky G</AU>
<TI>Effect of Ginkgo biloba extract in cases of arterial occlusive disease. Randomized placebo controlled crossover study</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1987</YR>
<VL>105</VL>
<NO>20</NO>
<PG>397-400</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:25:33 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandreau-1989" MODIFIED="2013-05-07 08:24:56 +0100" MODIFIED_BY="Cathryn  A Broderick" NAME="Sandreau 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-05-07 08:24:56 +0100" MODIFIED_BY="Cathryn  A Broderick" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saudreau F, Serise JM, Pillet J, Maiza D, Mercier V, Kretz JG, et al</AU>
<TI>Efficiency of Ginkgo-biloba extract in treatment of stages III (fontaine classification) chronic occlusive arterial diseases of the lower limbs</TI>
<SO>Journal des Maladies Vasculaires</SO>
<YR>1989</YR>
<VL>14</VL>
<NO>3</NO>
<PG>177-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schweizer-1999" MODIFIED="2008-09-23 12:25:45 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Schweizer 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-09-23 12:25:45 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schweizer J, Hautmann C</AU>
<TI>Comparison of two dosages of ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's stage IIb: A randomised, double-blind, multicentric clinical trial</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1999</YR>
<VL>49</VL>
<NO>11</NO>
<PG>900-4</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:25:45 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-05-08 09:52:05 +0100" MODIFIED_BY="Heather  Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2013-05-08 09:52:05 +0100" MODIFIED_BY="Heather  Maxwell">
<REFERENCE ID="REF-ATC-2002" MODIFIED="2008-09-17 12:18:08 +0100" MODIFIED_BY="[Empty name]" NAME="ATC 2002" TYPE="JOURNAL_ARTICLE">
<AU>Antithrombotic Trialist's Collaboration (ATC)</AU>
<TI>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients</TI>
<SO>British Medical Journal</SO>
<YR>2002</YR>
<VL>324</VL>
<NO>7329</NO>
<PG>71-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bauer-1986a" MODIFIED="2008-09-23 12:26:14 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Bauer 1986a" TYPE="JOURNAL_ARTICLE">
<AU>Bauer U</AU>
<TI>Ginkgo biloba extract in the treatment of arteriopathy of the lower extremities. A 65 week trial</TI>
<SO>Presse Medicale</SO>
<YR>1986</YR>
<VL>15</VL>
<NO>31</NO>
<PG>1546-9</PG>
<IDENTIFIERS MODIFIED="2008-09-23 12:26:14 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<REFERENCE ID="REF-Bauer-1986b" MODIFIED="2009-02-06 10:26:44 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Bauer 1986b" TYPE="CONFERENCE_PROC">
<AU>Bauer U</AU>
<TI>A two-year study of ginkgo biloba extract in the treatment of peripheral arterial disease (Fontaine stage IIb)</TI>
<SO>What is New in Angiology? Trends and Controversies</SO>
<YR>1986</YR>
<PG>531-2</PG>
<ED>Maurer PC, Becker HM, Heidrich H, Hoffmann G, Kriessmann A, Muller-Wiefel H, Pratorius C</ED>
<PB>Zuckschwerdt,W</PB>
<IDENTIFIERS MODIFIED="2008-09-23 12:26:29 +0100" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<REFERENCE ID="REF-Bauer-1986c" MODIFIED="2013-05-07 08:35:47 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Bauer 1986c" TYPE="JOURNAL_ARTICLE">
<AU>Bauer U</AU>
<TI>Long-term treatment of the peripheral arterial clasp illness with Ginkgo biloba extract (GBE); a 3-year-investigation</TI>
<TO>Langzeitbehandlung der peripheren arteriellen Verschlusskrankheit met Ginkgo biloba Extrakt (GBE); eine 3-Jahres-Untersuchung</TO>
<SO>Vasa</SO>
<YR>1986</YR>
<VL>15</VL>
<PG>S26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bendermacher-2005" MODIFIED="2013-05-07 09:06:37 +0100" MODIFIED_BY="[Empty name]" NAME="Bendermacher 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bendermacher BLW, Willigendael EM, Teijink JAW, Prins MH</AU>
<TI>Medical management of peripheral arterial disease</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>8</NO>
<PG>1628-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bendermacher-2006" MODIFIED="2013-04-17 10:56:20 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Bendermacher 2006" TYPE="COCHRANE_REVIEW">
<AU>Bendermacher BL, Willigendael EM, Teijink JA, Prins MH</AU>
<TI>Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-04-17 10:56:20 +0100" MODIFIED_BY="Heather  Maxwell">
<IDENTIFIER MODIFIED="2013-04-17 10:56:20 +0100" MODIFIED_BY="Heather  Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD005263.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Backer-2008" MODIFIED="2008-09-22 12:37:40 +0100" MODIFIED_BY="[Empty name]" NAME="de Backer 2008" TYPE="COCHRANE_REVIEW">
<AU>de Backer TL, Bogaert M, Vander Stichele R</AU>
<TI>Buflomedil for intermittent claudication</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-07-08 08:50:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-08 08:50:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000988.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Backer-2008a" MODIFIED="2008-07-08 08:52:15 +0100" MODIFIED_BY="[Empty name]" NAME="de Backer 2008a" TYPE="COCHRANE_REVIEW">
<AU>De Backer TLM, Vander Stichele R, Lehert P, Van Bortel L</AU>
<TI>Naftidrofuryl for intermittent claudication</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-08 08:52:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-08 08:52:15 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001368.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fontaine-1954" MODIFIED="2008-09-22 12:31:43 +0100" MODIFIED_BY="[Empty name]" NAME="Fontaine 1954" TYPE="JOURNAL_ARTICLE">
<AU>Fontaine R, Kim M, Kieny R</AU>
<TI>Surgical treatment for peripheral vascular disease</TI>
<TO>Die chirurgische Behandlung der peripheren Durchblutungsstörungen</TO>
<SO>Helvetica Chirurgica Acta</SO>
<YR>1954</YR>
<VL>5/6</VL>
<PG>499-533</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fowkes-1991" MODIFIED="2008-09-17 12:55:34 +0100" MODIFIED_BY="[Empty name]" NAME="Fowkes 1991" TYPE="JOURNAL_ARTICLE">
<AU>Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ</AU>
<TI>Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>2</NO>
<PG>384-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Girolami-1999" MODIFIED="2013-05-07 09:16:02 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Girolami 1999" TYPE="JOURNAL_ARTICLE">
<AU>Girolami B, Bernardi E, Prins MH, ten Cate JW, Hettiarachchi R, Prandoni P, et al</AU>
<TI>Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. A meta-analysis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>4</NO>
<PG>337-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hankey-2006" MODIFIED="2013-05-07 09:16:49 +0100" MODIFIED_BY="[Empty name]" NAME="Hankey 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hankey GJ, Norman PE, Eikelboom JW</AU>
<TI>Medical treatment of peripheral arterial disease</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>5</NO>
<PG>547-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2013-05-07 09:20:43 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0</SO>
<YR>2008</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hooi-1998" MODIFIED="2013-05-07 09:24:50 +0100" MODIFIED_BY="[Empty name]" NAME="Hooi 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hooi JD, Stoffers HEJH, Kester ADM, Rinkens PELM, Kaiser V, van Ree JW, et al</AU>
<TI>Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusion disease. The Limburg PAOD study. Peripheral Arterial Occlusive Disease</TI>
<SO>Scandinavian Journal of Primary Health Care</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>3</NO>
<PG>177-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horsch-2004" MODIFIED="2008-09-17 13:11:34 +0100" MODIFIED_BY="[Empty name]" NAME="Horsch 2004" TYPE="JOURNAL_ARTICLE">
<AU>Horsch S, Walther C</AU>
<TI>Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD) - a review based on randomized, controlled studies</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>42</VL>
<NO>2</NO>
<PG>63-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleijnen-1992" MODIFIED="2008-09-17 13:12:51 +0100" MODIFIED_BY="[Empty name]" NAME="Kleijnen 1992" TYPE="JOURNAL_ARTICLE">
<AU>Kleijnen J, Knipschild P</AU>
<TI>Ginkgo biloba</TI>
<SO>The Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<NO>8828</NO>
<PG>1136-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Korth-1988" MODIFIED="2013-05-07 09:28:06 +0100" MODIFIED_BY="[Empty name]" NAME="Korth 1988" TYPE="JOURNAL_ARTICLE">
<AU>Korth R, Nunez D, Bidault J, Benveniste J</AU>
<TI>Comparison of three paf-acether antagonist ginkgolides</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1988</YR>
<VL>152</VL>
<NO>1-2</NO>
<PG>101-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leng-2004" MODIFIED="2013-04-17 10:56:54 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Leng 2004" TYPE="COCHRANE_REVIEW">
<AU>Leng GC, Fowler B, Ernst E</AU>
<TI>Exercise for intermittent claudication</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-04-17 10:56:54 +0100" MODIFIED_BY="Heather  Maxwell">
<IDENTIFIER MODIFIED="2013-04-17 10:56:54 +0100" MODIFIED_BY="Heather  Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD000990"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Letzel-1992" MODIFIED="2008-09-17 13:32:44 +0100" MODIFIED_BY="[Empty name]" NAME="Letzel 1992" TYPE="JOURNAL_ARTICLE">
<AU>Letzel H, Schoop W</AU>
<TI>Gingko biloba extract EGb 761 and pentoxifylline in intermittent claudication. Secondary analysis of the clinical effectiveness</TI>
<TO>Ginkgo-biloba-Extrakt EGb 761 und Pentoxifyllin bei Claudicatio intermittens. Sekundäranalyse zur klinischen Wirksamkeit</TO>
<SO>VASA</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>4</NO>
<PG>403-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meijer-1998" MODIFIED="2013-05-08 09:52:05 +0100" MODIFIED_BY="Cathryn  A Broderick" NAME="Meijer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE</AU>
<TI>Peripheral arterial disease in the elderly: The Rotterdam Study</TI>
<SO>Arteriosclerosis, Thrombosis &amp; Vascular Biology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2000" MODIFIED="2008-09-17 13:35:36 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2000" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG</AU>
<TI>Pharmacological management of intermittent claudication: a meta-analysis of randomised trials</TI>
<SO>Drugs</SO>
<YR>2000</YR>
<VL>59</VL>
<NO>5</NO>
<PG>1057-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murabito-2002" NAME="Murabito 2002" TYPE="JOURNAL_ARTICLE">
<AU>Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW</AU>
<TI>Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study</TI>
<SO>American Heart Journal</SO>
<YR>2002</YR>
<VL>143</VL>
<NO>6</NO>
<PG>961-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pincemail-1989" NAME="Pincemail 1989" TYPE="JOURNAL_ARTICLE">
<AU>Pincemail J, Dupuis M, Nasr C, Hans P, Haag-Berrurier M, Anton R, et al</AU>
<TI>Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract</TI>
<SO>Experientia</SO>
<YR>1989</YR>
<VL>45</VL>
<NO>8</NO>
<PG>708-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pittler-2000" MODIFIED="2008-09-17 13:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Pittler 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pittler MH, Ernst E</AU>
<TI>Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials</TI>
<SO>The American journal of medicine</SO>
<YR>2000</YR>
<VL>108</VL>
<NO>4</NO>
<PG>276-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robak-1988" NAME="Robak 1988" TYPE="JOURNAL_ARTICLE">
<AU>Robak J, Gryglewski RJ</AU>
<TI>Flavonoids are scavengers of superoxide anions</TI>
<SO>Biochemical Pharmacology</SO>
<YR>1988</YR>
<VL>37</VL>
<NO>5</NO>
<PG>837-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robless-2008" MODIFIED="2013-04-17 10:59:45 +0100" MODIFIED_BY="[Empty name]" NAME="Robless 2008" TYPE="COCHRANE_REVIEW">
<AU>Robless P, Mikhailidis DP, Stansby GP</AU>
<TI>Cilostazol for peripheral arterial disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-07-08 08:46:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-08 08:46:51 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003748.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rutherford-1997" MODIFIED="2013-05-07 09:37:33 +0100" MODIFIED_BY="[Empty name]" NAME="Rutherford 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al</AU>
<TI>Recommended standards for reports dealing with lower extremity ischemia: revised version</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>3</NO>
<PG>517-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-1992" MODIFIED="2008-09-17 13:48:31 +0100" MODIFIED_BY="[Empty name]" NAME="Schneider 1992" TYPE="JOURNAL_ARTICLE">
<AU>Schneider B</AU>
<TI>Ginkgo biloba extract in peripheral arterial diseases. Meta-analysis of controlled clinical studies</TI>
<TO>Ginkgo-biloba-Extraxt bei peripheren arteriellen Verschlusskrankheiten; Meta-analyse von kontrolierten klinischen Studien</TO>
<SO>Arzneimittel-Forschung</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>4</NO>
<PG>428-36</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-05-07 09:39:29 +0100" MODIFIED_BY="Cathryn  A Broderick">
<REFERENCE ID="REF-Cochrane-2009" MODIFIED="2013-05-07 09:39:29 +0100" MODIFIED_BY="Cathryn  A Broderick" NAME="Cochrane 2009" TYPE="COCHRANE_REVIEW">
<AU>Nicolaï SP, Kruidenier LM, Bendermacher BL, Prins MH, Teijink JA</AU>
<TI>Ginkgo biloba for intermittent claudication</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-04-17 10:39:22 +0100" MODIFIED_BY="Cathryn  A Broderick">
<IDENTIFIER MODIFIED="2013-04-17 10:39:22 +0100" MODIFIED_BY="Cathryn  A Broderick" TYPE="DOI" VALUE="10.1002/14651858.CD006888.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2008-07-18 15:14:03 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-05-28 11:51:45 +0100" MODIFIED_BY="Heather  Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-05-28 11:51:45 +0100" MODIFIED_BY="Heather  Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-05-28 11:46:46 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Bauer-1984">
<CHAR_METHODS MODIFIED="2008-09-23 13:33:34 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.<BR/>
<BR/>Method of randomisation: divided at random.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-28 11:46:46 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: Germany.<BR/>
<BR/>Setting: outpatient setting.<BR/>
<BR/>Number randomised: 79 (treatment group: 44, control group: 35).<BR/>
<BR/>Age: mean 60.9 years.<BR/>
<BR/>Sex: 61 males and 18 females.<BR/>
<BR/>Inclusion criteria: patients with PAD (stage IIb according to Fontaine), predominantly on one site, lasting &gt; 1 year; ACD less than or equal to 300 metres.<BR/>
<BR/>Exclusion criteria: Unco-operative patients; patients with other vaso-active medication; other stage of Fontaine&#8217;s classification; concomitant illness: pathology of the veins; anaemia; non compensated cardiac insufficiency; recent myocardial infarction; uncontrolled hypertension; other causes of walking impairment; poorly controlled diabetes; important kidney or hepatic insufficiency; recent treatment with anticoagulant drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-09 16:06:54 +0000" MODIFIED_BY="Heather  Maxwell">
<P>Treatment: 40 mg GbE three times daily. (Coated tablets containing 40 mg GbE. Manufacturer: Intersan, Institut für pharmazeutische und Klinische Forschung GmbH, Ettlingen, Germany)</P>
<P>Control: placebo.</P>
<P>Duration: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:45:24 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD by treadmill testing (3 km/h and 10% incline); subjective estimate of pain by a VAS; plethysmography; systolic ankle pressures at rest and after exercise; tolerance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-31 12:39:36 +0000" MODIFIED_BY="[Empty name]">
<P>In three other articles the clinical course is described of the treatment group after 1 year (<LINK REF="REF-Bauer-1986a" TYPE="REFERENCE">Bauer 1986a</LINK>), 2 years (<LINK REF="REF-Bauer-1986b" TYPE="REFERENCE">Bauer 1986b</LINK>) and 3 years (<LINK REF="REF-Bauer-1986c" TYPE="REFERENCE">Bauer 1986c</LINK>). However, the control group is not mentioned.</P>
<P>Funding: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-28 11:47:27 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Blume-1996">
<CHAR_METHODS MODIFIED="2008-09-23 13:33:51 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: EPD number generator.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-16 13:49:21 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: Germany.</P>
<P>Setting: ambulant patient seeking consultation at a angiological practice.</P>
<P>Number randomised: 60 (treatment group: 30, control group: 30).</P>
<P>Age: aged between 47 and 82, median treatment group 71 (95% CI 65.2 to 74.8), median control group 68.6 (95% CI 65.5 to 73.2).</P>
<P>Sex: 42 males and 18 females.</P>
<P>Inclusion criteria: patients with PAD (stage IIb according to Fontaine) angiographically confirmed; stable walking distance in spite of constant walking training; ICD less than 150 metres.</P>
<P>Exclusion criteria: age &lt; 18 years; cardiac infarction during the preceding 6 months; NYHA stage III or IV cardiac insufficiency; diastolic pressure &gt; 120 mmHg; renal insufficiency; functional hepatic disorders; respiratory insufficiency or orthopaedic disorder as limiting factor of the walking distance; venous insufficiency stage II (Basle Classification; badly manageable diabetes mellitus; anaemia; hematocrit &gt; 48%; fibrinogen &gt; 500 mg/dl; use of platelet aggregation inhibitor; anti-inflammatory agents or analgesics; pregnancy or expected insufficient compliance.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-28 11:47:27 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 40 mg Ginkgo biloba special extract GbE 761 three times daily. (40 mg film-coated tablet containing dry extract from Ginkgo biloba leaves (50:1) 40 mg, adjusted at 9.6 mg Ginkgo flavone glycosides and 2.4 mg terpene lactones (ginkgolides, bilobalide). Manufacturer: Dr. Wilmar Schwabe Arzneimittel / Pharmaceuticals, Karlsruhe, Germany).</P>
<P>Control: placebo.<BR/>Duration: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:45:35 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD by treadmill testing (3 km/h and 12% incline); ABI; subjective estimate of pain by a VAS; adverse drug reactions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-07 13:54:32 +0100" MODIFIED_BY="[Empty name]">
<P>Maximum level trained patients with IC.</P>
<P>Funding: not stated.</P>
<P>Conflicts of interests: One of the authors is employed by one of the manufacturers Dr. Willmar Schwabe, Karlsruhe, Germany.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-09 10:45:40 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Blume-1998">
<CHAR_METHODS MODIFIED="2008-09-23 13:36:47 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-23 13:36:57 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: Germany.</P>
<P>Setting: not stated.</P>
<P>Number randomised: 41 (treatment group 21, control group 20).</P>
<P>Age: mean treatment group 66.4, mean control group 68.2.</P>
<P>Sex: treatment group 14 males and 7 females, control group 15 males and 4 females.</P>
<P>Inclusion criteria: patients with PAD (stage IIb according to Fontaine) angiographically confirmed. PAD &gt; 6 months present.</P>
<P>Exclusion criteria: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-08 09:39:55 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Treatment: 80 mg Ginkgo biloba special extract EgB 761 two times daily. (80 mg film-coated tablet containing dry extract from Ginkgo biloba leaves (35-67:1) 80 mg, standardised at 19.2 mg Ginkgo flavone glycosides and 4.8 mg terpene lactones (ginkgolides, bilobalide).<BR/>Manufacturer: Dr. Wilmar Schwabe Arzneimittel / Pharmaceuticals, Karlsruhe, Germany).</P>
<P>Control: placebo.</P>
<P>Duration: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:45:40 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD by treadmill testing (3 km/h and 12% incline); tolerance of Ginkgo biloba special extract EgB 761.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-07 13:55:05 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not stated.</P>
<P>Conflicts of interests: One of the authors is employed by one of the manufacturers Dr. Willmar Schwabe, Karlsruhe, Germany.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-28 11:48:11 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Bulling-1991">
<CHAR_METHODS MODIFIED="2008-09-23 13:37:20 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-09 16:11:18 +0000" MODIFIED_BY="Heather  Maxwell">
<P>Country: Germany.</P>
<P>Setting: outpatient setting.</P>
<P>Number randomised: 36, 33 were evaluated, treatment group 17, control group 16.</P>
<P>Age: mean treatment group 62.8, mean control group 63.3.</P>
<P>Sex: treatment group; 12 males and 5 females, control group; 12 males and 4 females.</P>
<P>Inclusion criteria: patients with PAD (stage IIb according to Fontaine); ICD at least 50 metres and at most 200 metres.</P>
<P>Exclusion criteria: venous complaints; anaemia; decompensated cardiac insufficiency; unstable angina pectoris; coronary heart disease; respiratory insufficiency; non-controlled hypertension; recent myocardial infarction; badly adjustable diabetes; disease of liver and kidneys; orthopaedic reason for walking restriction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-28 11:48:11 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Treatment: standardised Ginkgo biloba extract 761. (The drug extract ratio is 50:1, the standardised content of flavone glycosides is 24% (9.6 mg/40 mg extract), and that of terpene lactones 6% (2.4 mg/40 mg extract) Rökan®)</P>
<P>Control: placebo.</P>
<P>Duration: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:45:44 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD by treadmill testing (3 km/h and 10% incline); number of "tip-toe" stands; systolic ankle pressure in the posterior tibial artery; plasma viscosity and haematocrit; adverse reactions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-07 13:55:48 +0100" MODIFIED_BY="[Empty name]">
<P>All patients received exercise therapy in combination with participation in this trial.</P>
<P>Funding: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-28 11:49:09 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Diehm-1990">
<CHAR_METHODS MODIFIED="2008-09-23 13:39:38 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: computerised randomisation program.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-28 11:48:42 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: Germany.</P>
<P>Setting: not stated.</P>
<P>Number randomised: 40, treatment group 22, control group 18.</P>
<P>Age: mean treatment group 62.2, mean control group 63.0.</P>
<P>Sex: treatment group; 21 males and 1 female, control group; 17 males and 1 female.</P>
<P>Inclusion criteria: Patients with PAD (stage IIb according to Fontaine); ICD of 50 to 200 m; age between 40 and 75 years; precisely reproducible pain localization under exercise; pressure in posterior tibial artery &gt; 50 mmHg; ABI &lt; 0.85; Broca deviation &lt; 30 %; abstinence from nicotine.</P>
<P>Exclusion criteria: myocardial infarction within half a year before enrolment; heart failure NYHA III or IV; severe chronic venous insufficiency; insufficiently controllable diabetes mellitus; malabsorption; liver disorder: transaminase levels above 3 times the upper limit of the normal range; renal disorder: serum creatinin level above 3.0 mg/dl; gait impairment due to orthopaedic or neurological diseases; respiratory insufficiency limiting walking distance; angina pectoris limiting walking distance; uncontrolled hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-23 13:40:00 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Treatment: 120 mg Ginkgo biloba special extract EgB 761 daily.</P>
<P>Control: placebo.</P>
<P>Duration: 12 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:45:53 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD by treadmill testing (5 km/h and 10% incline); adverse reactions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-28 11:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>Conflicts of interests: Internal rapport of Dr. Wilmar Schwabe Arzneimittel/Pharmaceuticals, Karlsruhe, Germany.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-09 10:46:03 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Drabaek-1996">
<CHAR_METHODS MODIFIED="2008-12-31 12:52:00 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: double blind randomised cross-over study.</P>
<P>Method of randomisation: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-07 13:57:26 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: Denmark.</P>
<P>Setting: Not stated.</P>
<P>Number randomised: 18.</P>
<P>Age: 59 to 82 years (median age 74).</P>
<P>Sex: not stated.</P>
<P>Inclusion criteria: Stable form of IC more than 6 months; ACD 50 to 500 metres; ABI &lt; 0.85.</P>
<P>Exclusion criteria: Chronic obstructive pulmonary disease; diabetes mellitus; artrosis; angina pectoris; cardiac insufficiency.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-08 09:40:46 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Treatment: 120 mg GbE GB 8 daily.</P>
<P>Control: placebo.</P>
<P>Duration:6 months, 3 months treatment and 3 months placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:46:03 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD by treadmill testing (individual speed (2.5 to 4 km/h) and incline (8 to 16% incline); ABI; subjective estimate of pain by a VAS; cognitive functions: concentration and short term memory.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-07 13:57:46 +0100" MODIFIED_BY="[Empty name]">
<P>Only the first study period (3 months) before the cross-over is considered.</P>
<P>Funding: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-09 10:46:10 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Gardner-2008">
<CHAR_METHODS MODIFIED="2008-09-23 13:42:32 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: computerised randomisation program.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-10 12:47:25 +0000" MODIFIED_BY="Heather  Maxwell">
<P>Country: USA.</P>
<P>Setting: patients recruited from the local community through advertisement.</P>
<P>Number randomised: 62, treatment group 31, control group 31.</P>
<P>Age: mean treatment group 69, mean control group 70.</P>
<P>Sex: treatment group 13 males and 18 females, control group 24 males and 7 females.</P>
<P>Inclusion criteria: Patients with a resting ABI &lt; 0.90; ACD between 1 and 10 minutes; drop in ABI after exercise of at least 25%. (For diabetics all ABI values were allowed).</P>
<P>Exclusion criteria: major surgery; chronic disease in the last three months; use of pentoxifylline, carnitine, arginine, prostacycline, dietary antioxidant supplements, supplements containing Ginkgo biloba.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-07 13:58:34 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Treatment: 300 mg standardised Ginkgo biloba extract 761 daily (180 mg with breakfast and 120 mg with dinner). (60 mg tablet standardised at 24% Ginkgo flavone glycosides and 6% terpene lactones. Manufacturer: Dr. Wilmar Schwabe Arzneimittel/Pharmaceuticals, Karlsruhe, Germany).</P>
<P>Control: placebo.</P>
<P>Duration: 4 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:46:10 +0100" MODIFIED_BY="Heather  Maxwell">
<P>ABI; walking distance: ACD and ICD by treadmill testing (3.2 km/h and 10% incline); flow-mediated vasodilatation of the brachial artery; antibodies to epitopes of oxidized LDL; walking impairment questionnaire; QoL: MOS SF-36 questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-31 13:02:25 +0000" MODIFIED_BY="[Empty name]">
<P>Funding: NIH grant R01 AT002004. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-09 10:46:15 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Mouren-1994">
<CHAR_METHODS MODIFIED="2013-04-17 10:43:00 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: not stated </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-09 10:46:15 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: France.</P>
<P>Setting: patients recruited from the outpatient clinic.</P>
<P>Number randomised: 20.</P>
<P>Age: not stated.</P>
<P>Sex: not stated.</P>
<P>Inclusion criteria: patients between the ages of 35 and 75 years suffering from IC (stage II according to Fontaine); diagnosed for more than 1 year; stable for three months; ACD on treadmill (3.2 km/h and 10% incline) &gt; 100 metres and &lt; 500 metres; transcutaneous partial pressure of oxygen in rest &gt; 40 mmHg.</P>
<P>Exclusion criteria: Patients with stage III and IV arterial disease; recent acute arterial occlusion; any form of peripheral circulatory insufficiency due to causes other than atherosclerosis; planned surgical revascularisation; decompensated heart failure; coronary insufficiency; poorly controlled hypertension; locomotor handicap.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-23 13:45:11 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Treatment: 160 mg EGb 761 two times daily.</P>
<P>Control: placebo.</P>
<P>Duration: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-07 13:59:38 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Transcutaneous partial pressure of oxygen in rest; transcutaneous partial pressure of oxygen after exercise; functional impairment by VAS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-31 13:03:39 +0000" MODIFIED_BY="[Empty name]">
<P>Although walking distances were not reported, functional impairment as measured by a VAS was used for the analysis.</P>
<P>Funding: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-09 10:46:20 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Natali-1985">
<CHAR_METHODS MODIFIED="2008-09-23 13:46:04 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-09 16:18:58 +0000" MODIFIED_BY="Heather  Maxwell">
<P>Country: France.</P>
<P>Setting: outpatient setting.</P>
<P>Number randomised: 18, treatment group 9, control group 9.</P>
<P>Age: treatment group 60.8, control group 66.2.</P>
<P>Sex: treatment group 7 males and 2 females, control group 8 males and 1 female.</P>
<P>Inclusion criteria: Patients with PAD (stage IIb according to Fontaine); age 30 to 75 years; occlusive lesions of deep femoral arteries verified by arteriography; stable condition.</P>
<P>Exclusion criteria: non co-operative patient; significant psychiatric disorder; physical condition that does not allow exercise tests to be performed; any other ailment that could influence the course of the PAD or interfere with the assessment of treatment effects (e.g. Parkinson's disease, tumours); treatment of the same type as the product studied; treatment that could interfere with the assessment of treatment effects. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-23 13:46:32 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Treatment: 160 mg Ginkgo biloba special extract EgB 761 daily.</P>
<P>Control: placebo.</P>
<P>Duration: 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:46:20 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD by treadmill testing (3 km/h and 5% incline); adverse reactions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-07 14:00:35 +0100" MODIFIED_BY="[Empty name]">
<P>Conflicts of interests: Internal rapport of Dr. Wilmar Schwabe Arzneimittel/Pharmaceuticals, Karlsruhe, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-28 11:51:45 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Peters-1998">
<CHAR_METHODS MODIFIED="2008-09-23 13:47:29 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: assigned at random.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-28 11:51:27 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: Germany.</P>
<P>Setting: multicenter study.</P>
<P>Number randomised: 109, treatment group 52, control group 59.</P>
<P>Age: mean treatment group 62.8, mean control group 61.2.</P>
<P>Sex: treatment group 29 males and 23 females, control group 34 males and 23 females.</P>
<P>Inclusion criteria: Patients with PAD (stage IIb according to Fontaine) angiographically confirmed; older than 18 years; IC for more than 6 months; ICD &lt; 150 metres.</P>
<P>Exclusion criteria: severe impairment of heart, liver and/or kidney; walking limitation due to respiratory insufficiency or orthopaedic disorder; poorly controlled diabetes; pathologically altered hemorrheology; drugs for the same indication as the test substance; use of platelet aggregation inhibitors; anti-inflammatories; or analgesics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-28 11:51:45 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 40 mg standardised Egb 761 three times daily. (1 film-coated tablet contains 40 mg special extract EGb 761 from Ginkgo biloba leaves (35-67:1), standardised to 9.6 mg (24%) of ginkgo flavone glycosieds and 2.4 (6%) to terpene lactones. Manufacturer: Dr. Wilmar Schwabe Arzneimittel/Pharmaceuticals, Karlsruhe, Germany).</P>
<P>Control: placebo.</P>
<P>Duration: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:46:26 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD by treadmill testing (3 km/h and 12% incline); ABI; subjective assessment of therapeutic outcome using VAS; tolerance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-31 13:08:03 +0000" MODIFIED_BY="[Empty name]">
<P>During the course of thee study, participation in a walking exercise program was offered for all patients.</P>
<P>Funding: Not stated.</P>
<P>Conflicts of interests: One of the authors is employed by one of the manufacturers Dr. Willmar Schwabe, Karlsruhe, Germany.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-07 14:01:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salz-1980">
<CHAR_METHODS MODIFIED="2008-09-23 13:48:33 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised cross-over study.</P>
<P>Method of randomisation: assigned at random.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-23 13:48:40 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: Germany.</P>
<P>Setting: not stated.</P>
<P>Number randomised: 29, treatment group 13, control group 13.</P>
<P>Age: mean age males 69.0, mean age females 64.4.</P>
<P>Sex: 11 males and 18 females.</P>
<P>Inclusion criteria: Patients with PAD (stage IIb according to Fontaine) in both legs.</P>
<P>Exclusion criteria:not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-07 14:01:34 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 40 mg standardised Egb 761 two times daily 2 tablets. (Rökan®).</P>
<P>Control: placebo.</P>
<P>Duration: two times 6 week cross-over study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-23 13:49:13 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD assessed by walking with 2 steps per second; Ratschow-test; maximal time of toe-standing; temperature of the skin; laboratory parameters.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-07 14:01:42 +0100" MODIFIED_BY="[Empty name]">
<P>Only the first study period (6 weeks) before the cross-over is considered.</P>
<P>Funding: Not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-09 10:46:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schoop-1997">
<CHAR_METHODS MODIFIED="2008-09-23 13:49:48 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-23 13:49:56 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: Germany.</P>
<P>Setting: not stated.</P>
<P>Number randomised: 205, treatment group 105, control group 100.</P>
<P>Age: mean treatment group 64.3, mean control group 67.2.</P>
<P>Sex: treatment group 80 males and 25 females, control group 77 males and 23 females.</P>
<P>Inclusion criteria: Patients with PAD (stage IIb according to Fontaine).</P>
<P>Exclusion criteria: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-08 09:36:49 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 40 mg standardised GbE three times daily. (1 film-coated tablet contains 40 mg dry extract from Ginkgo biloba leaves (50:1), standardised to 9.6 mg of ginkgo flavone glycosieds and 2.4 to terpene lactones. (ginkgolides, bilobalide). Manufacturer: not stated).</P>
<P>Control: placebo.</P>
<P>Duration: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:46:33 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ICD by treadmill testing (3 km/h and 12% incline); tolerance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-07 14:02:14 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-09 10:46:37 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Thomson-1990">
<CHAR_METHODS MODIFIED="2008-09-23 13:50:15 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: randomly allocated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-09 16:20:33 +0000" MODIFIED_BY="Heather  Maxwell">
<P>Country: United Kingdom.</P>
<P>Setting: not stated.</P>
<P>Number randomised: 49, treatment group 25, control group 24.</P>
<P>Age: not stated.</P>
<P>Sex: not stated.</P>
<P>Inclusion criteria: Patients with PAD (stage IIb according to Fontaine) affecting the iliac or femoral arteries, involving predominantly one leg.</P>
<P>Exclusion criteria: ICD &gt; 300 metres; alternating side of pain; poorly controlled diabetes; significant concomitant illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-05 10:10:33 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: Ginkgo biloba extract (Tanakan®).</P>
<P>Control: placebo.</P>
<P>Duration: 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:46:37 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ICD by treadmill testing (4 km/h and 10 degrees (= 17.6% incline)); recovery times; systolic ankle pressure at rest and after exercise; tolerance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-07 14:02:50 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: The work was supported and assisted by Ipsen International (one of the manufacturers).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-09 10:46:49 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Wang-2007">
<CHAR_METHODS MODIFIED="2008-09-23 13:51:10 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Study design: double blind randomised clinical trial.</P>
<P>Method of randomisation: randomly allocated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-09 10:46:42 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: Australia.</P>
<P>Setting: not stated.</P>
<P>Number randomised: 22, treatment group 11, control group 11.</P>
<P>Age: mean treatment group 71.6, mean control group 71.2.</P>
<P>Sex: treatment group 9 males and 2 females, control group 11 males.</P>
<P>Inclusion criteria: Patients with stable IC for at least 6 months; 50-80 years of age; ABI at rest &lt; 0.90 and after exercise &lt; 0.80.</P>
<P>Exclusion criteria: resting ischaemic pain; ulceration; gangrene; unable to walk on treadmill with 3.2 km/h, exercise capacity limited by angina; congestive heart failure; chronic obstructive pulmonary disease or arthritis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-08 09:53:09 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 240 mg standardised GbE 761 daily. (The Ginkgo biloba tablets were standardized to 26.7% ginkgo flavone glycosides and 6.7% terpenoids (ginkgolides or bilobalide). Manufacturer: not stated).</P>
<P>Control: placebo.</P>
<P>Duration: 12 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 10:46:49 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Walking distance: ACD and ICD by treadmill testing (3.2 km/h and 0% incline); ABI in rest and after exercise; plasma viscosity; whole blood viscosity; peak VO<SUB>2; </SUB>walking economy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-08 09:42:15 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Only the first 12 weeks of the study in which Ginkgo biloba treatment was compared with placebo is considered. The second part was a 12-week supervised treadmill walking programme, while the subjects continued taking the same dosage of Ginkgo biloba or placebo.</P>
<P>Funding: The Ginkgo biloba and placebo tablets were kindly donated by Mayne Health Consumer Products, Australia.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ABI: ankle brachial index<BR/>ACD: absolute claudication distance<BR/>GbE: Ginkgo biloba extract<BR/>ICD: initial claudication distance<BR/>LDL: low density lipoprotein<BR/>PAD: peripheral arterial disease<BR/>VAS: visual analogue scale<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-05-08 09:42:57 +0100" MODIFIED_BY="Heather  Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-09-23 13:55:22 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Ambrosi-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-23 13:55:22 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Separate data for patients diagnosed with PAD stage II according to Fontaine were not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-09 16:21:49 +0000" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Baitsch-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-09 16:21:48 +0000" MODIFIED_BY="Heather  Maxwell">
<P>This study compares Ginkgo biloba extract with dextran in patients with PAD stage IV according to Fontaine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-09 16:21:45 +0000" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Berndt-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-09 16:21:45 +0000" MODIFIED_BY="Heather  Maxwell">
<P>Ginkgo biloba extract is compared with buflomedil.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-23 13:55:54 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Bohmer-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-23 13:55:54 +0100" MODIFIED_BY="Heather  Maxwell">
<P>(According to Fontaine), diagnosed for more than 1 year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-23 13:55:58 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Courbier-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-23 13:55:58 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Separate data for patients diagnosed with PAD stage II according to Fontaine were not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-23 13:56:04 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Frileux-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-23 13:56:04 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Separate data for patients diagnosed with PAD stage II according to Fontaine were not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-23 13:56:08 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Garzya-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-23 13:56:08 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Separate data for patients diagnosed with PAD stage II according to Fontaine were not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-09 16:22:11 +0000" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Horsch-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-09 16:22:11 +0000" MODIFIED_BY="Heather  Maxwell">
<P>Ginkgo biloba extract is compared with naftidrofuryl in patients with PAD stage III and IV according to Fontaine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-23 13:56:13 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Li-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-23 13:56:13 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Primary aim of this study was to compare diabetic and non-diabetic PAD patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-23 13:56:15 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Michelini-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-23 13:56:15 +0100" MODIFIED_BY="Heather  Maxwell">
<P>This study compares the combination of Ginkgo biloba extract, magnesium and Levo-arginine with acetylsalicyl acid.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-23 13:56:18 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Rudofsky-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-23 13:56:18 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Double blind randomised cross-over study evaluating the short term effect (60 minutes) of Ginkgo biloba extract versus placebo in patients with PAD stage II according to Fontaine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-08 09:42:57 +0100" MODIFIED_BY="Cathryn  A Broderick" STUDY_ID="STD-Sandreau-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-08 09:42:57 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>This study only included patients diagnosed with PAD stage III according to Fontaine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-23 13:56:20 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Schweizer-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-23 13:56:20 +0100" MODIFIED_BY="Heather  Maxwell">
<P>This study compares two dosages of Ginkgo biloba extract without a placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-09-11 15:07:09 +0100" MODIFIED_BY="Heather  Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-09-11 15:07:10 +0100" MODIFIED_BY="Heather  Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-05-07 13:59:57 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-05-07 13:59:57 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:33:14 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Bauer-1984">
<DESCRIPTION>
<P>Patients were divided at random into 2 equal groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:36:33 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="YES" STUDY_ID="STD-Blume-1996">
<DESCRIPTION>
<P>Patients were randomly assigned using an EPD random number generator was used for allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-06 16:40:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blume-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:39:24 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Bulling-1991">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-14 14:56:27 +0000" MODIFIED_BY="Heather  Maxwell" RESULT="YES" STUDY_ID="STD-Diehm-1990">
<DESCRIPTION>
<P>Patients were randomised with a computerised randomisation program.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-07 13:57:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drabaek-1996">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:43:49 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="YES" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>Randomisation was performed by generating random numbers assigned to treatment and control and assigning each new participant the next number in sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-07 13:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mouren-1994">
<DESCRIPTION>
<P>Randomisation was performed by random number generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:46:46 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Natali-1985">
<DESCRIPTION>
<P>Patients were randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:48:18 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1998">
<DESCRIPTION>
<P>Patients were assigned at random.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:49:20 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="YES" STUDY_ID="STD-Salz-1980">
<DESCRIPTION>
<P>Patients were assigned to the trial according to a random code van 1 to 30 in a consecutive way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:50:10 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Schoop-1997">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:51:04 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Thomson-1990">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:52:24 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="YES" STUDY_ID="STD-Wang-2007">
<DESCRIPTION>
<P>Subjects were randomly allocated following a randomisation code. The code was created by a computerised program.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-05-07 13:57:52 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:33:15 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Bauer-1984">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:36:38 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Blume-1996">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-06 16:40:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blume-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:39:25 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Bulling-1991">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-07 13:56:47 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Diehm-1990">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-07 13:57:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drabaek-1996">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:43:50 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:45:50 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Mouren-1994">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:46:43 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Natali-1985">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:48:19 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1998">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:49:21 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Salz-1980">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:50:10 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Schoop-1997">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:51:05 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Thomson-1990">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-23 13:52:25 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="YES" STUDY_ID="STD-Wang-2007">
<DESCRIPTION>
<P>The code was administered by a third party who was not involved in the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-05-07 13:57:54 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-23 13:33:18 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Bauer-1984">
<DESCRIPTION>
<P>The placebo group received matching placebo tablets which were taken in the same manner.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-06 16:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blume-1996">
<DESCRIPTION>
<P>There was an externally indistinguishable placebo and neither the patient nor the examiner or any other person directly involved in the study was able to see which group a patient belonged to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-06 16:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blume-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-23 13:39:25 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Bulling-1991">
<DESCRIPTION>
<P>The placebo tablets had an identical appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-14 14:56:42 +0000" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Diehm-1990">
<DESCRIPTION>
<P>Tablets of identical appearance, packed and labelled in identical way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-07 13:57:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drabaek-1996">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-16 13:52:36 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="YES" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>Subjects, study staff, and laboratory technicians were blinded to treatment assignments until the conclusions of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-23 13:45:51 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Mouren-1994">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-23 13:47:20 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Natali-1985">
<DESCRIPTION>
<P>The intervention and the placebo were presented the same way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-23 13:48:19 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1998">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-23 13:49:21 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Salz-1980">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-23 13:50:11 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Schoop-1997">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-23 13:51:06 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Thomson-1990">
<DESCRIPTION>
<P>Randomisation to Ginkgo biloba or placebo was made in a double blind manner.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-23 13:52:28 +0100" MODIFIED_BY="Heather  Maxwell" RESULT="YES" STUDY_ID="STD-Wang-2007">
<DESCRIPTION>
<P>The code was revealed to the subject and the researcher after the database of the study was completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-04 10:41:06 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-04 10:41:06 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Ginkgo biloba versus placebo</NAME>
<CONT_OUTCOME CHI2="25.68630473050447" CI_END="7.228747453883378" CI_START="-0.09508511481064463" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="3.566831169536367" ESTIMABLE="YES" I2="61.06874809390458" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2008-07-04 10:41:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0041858122296991596" P_Q="1.0" P_Z="0.056252846949720284" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="19.953930260032514" TOTALS="YES" TOTAL_1="246" TOTAL_2="231" UNITS="" WEIGHT="100.00000000000001" Z="1.909071668598443">
<NAME>Absolute claudication distance (expressed as kilocalories) at the end of the study</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.781524361941504" CI_START="-1.9815243619415055" EFFECT_SIZE="5.899999999999999" ESTIMABLE="YES" MEAN_1="25.7" MEAN_2="19.8" MODIFIED="2008-05-21 10:22:17 +0100" MODIFIED_BY="[Empty name]" ORDER="60" SD_1="15.5" SD_2="18.8" SE="4.021259790542052" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="33" WEIGHT="9.663162225643452"/>
<CONT_DATA CI_END="7.62845813731568" CI_START="-0.42845813731567706" EFFECT_SIZE="3.6000000000000014" ESTIMABLE="YES" MEAN_1="26.8" MEAN_2="23.2" MODIFIED="2008-07-04 10:39:11 +0100" MODIFIED_BY="[Empty name]" ORDER="61" SD_1="8.0" SD_2="7.1" SE="2.0553735523160843" STUDY_ID="STD-Blume-1996" TOTAL_1="28" TOTAL_2="26" WEIGHT="14.43748193681138"/>
<CONT_DATA CI_END="11.772133761460378" CI_START="0.027866238539624" EFFECT_SIZE="5.9" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="15.1" MODIFIED="2008-05-28 08:39:42 +0100" MODIFIED_BY="[Empty name]" ORDER="62" SD_1="10.6" SD_2="8.3" SE="2.9960416659586695" STUDY_ID="STD-Blume-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="12.066165180817855"/>
<CONT_DATA CI_END="30.721029053515764" CI_START="-2.721029053515764" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="48.4" MEAN_2="34.4" MODIFIED="2008-07-04 10:39:10 +0100" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="25.7" SD_2="23.3" SE="8.531294036731852" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="3.7641595941213875"/>
<CONT_DATA CI_END="6.852838969325953" CI_START="-4.852838969325953" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="25.4" MEAN_2="24.4" MODIFIED="2008-05-21 10:16:24 +0100" MODIFIED_BY="[Empty name]" ORDER="64" SD_1="7.5" SD_2="10.7" SE="2.986197203363123" STUDY_ID="STD-Diehm-1990" TOTAL_1="22" TOTAL_2="18" WEIGHT="12.090777845229841"/>
<CONT_DATA CI_END="12.438071813664346" CI_START="-13.438071813664346" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="23.8" MEAN_2="24.3" MODIFIED="2008-05-28 09:02:11 +0100" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="13.7" SD_2="14.3" SE="6.601178345989112" STUDY_ID="STD-Drabaek-1996" TOTAL_1="9" TOTAL_2="9" WEIGHT="5.494716638318567"/>
<CONT_DATA CI_END="24.0644118130569" CI_START="-3.864411813056906" EFFECT_SIZE="10.099999999999998" ESTIMABLE="YES" MEAN_1="33.4" MEAN_2="23.3" MODIFIED="2008-05-21 10:14:08 +0100" MODIFIED_BY="[Empty name]" ORDER="66" SD_1="33.9" SD_2="16.2" SE="7.124830825059236" STUDY_ID="STD-Gardner-2008" TOTAL_1="28" TOTAL_2="27" WEIGHT="4.936236113279691"/>
<CONT_DATA CI_END="31.89747452386768" CI_START="-1.6974745238676778" EFFECT_SIZE="15.1" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="12.9" MODIFIED="2008-05-21 10:11:25 +0100" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="24.3" SD_2="8.4" SE="8.570297544426332" STUDY_ID="STD-Natali-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="3.737278739373399"/>
<CONT_DATA CI_END="8.037367713085752" CI_START="-0.6373677130857534" EFFECT_SIZE="3.6999999999999993" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="22.3" MODIFIED="2008-07-04 10:39:10 +0100" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="10.9" SD_2="11.1" SE="2.2129833748468624" STUDY_ID="STD-Peters-1998" TOTAL_1="47" TOTAL_2="52" WEIGHT="14.04665215577092"/>
<CONT_DATA CI_END="17.994505142797923" CI_START="0.005494857202076986" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="25.6" MEAN_2="16.6" MODIFIED="2008-05-28 09:29:38 +0100" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="11.7" SD_2="11.7" SE="4.589117562233506" STUDY_ID="STD-Salz-1980" TOTAL_1="13" TOTAL_2="13" WEIGHT="8.511169754314068"/>
<CONT_DATA CI_END="-4.179170728085825" CI_START="-17.220829271914173" EFFECT_SIZE="-10.7" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="23.5" MODIFIED="2008-07-04 10:41:06 +0100" MODIFIED_BY="[Empty name]" ORDER="69" SD_1="6.1" SD_2="7.6" SE="3.327014844838805" STUDY_ID="STD-Wang-2007" TOTAL_1="8" TOTAL_2="9" WEIGHT="11.252199816319457"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.4012869114568876" CI_END="7.16498967317988" CI_START="2.2728704211004707" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="4.718930047140176" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2008-06-19 09:47:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6383740239810094" P_Q="1.0" P_Z="1.5610183750934686E-4" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="166" TOTAL_2="155" UNITS="" WEIGHT="100.0" Z="3.78115596181649">
<NAME>Absolute claudication distance (expressed as kilocalories) after 24 weeks</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.781524361941504" CI_START="-1.9815243619415055" EFFECT_SIZE="5.899999999999999" ESTIMABLE="YES" MEAN_1="25.7" MEAN_2="19.8" MODIFIED="2008-05-20 16:04:56 +0100" MODIFIED_BY="[Empty name]" ORDER="1" SD_1="15.5" SD_2="18.8" SE="4.021259790542052" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="33" WEIGHT="9.631937017109408"/>
<CONT_DATA CI_END="7.62845813731568" CI_START="-0.42845813731567706" EFFECT_SIZE="3.6000000000000014" ESTIMABLE="YES" MEAN_1="26.8" MEAN_2="23.2" MODIFIED="2008-05-20 16:06:19 +0100" MODIFIED_BY="[Empty name]" ORDER="2" SD_1="8.0" SD_2="7.1" SE="2.0553735523160843" STUDY_ID="STD-Blume-1996" TOTAL_1="28" TOTAL_2="26" WEIGHT="36.86857642123188"/>
<CONT_DATA CI_END="11.772133761460378" CI_START="0.027866238539624" EFFECT_SIZE="5.9" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="15.1" MODIFIED="2008-05-28 08:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="10.6" SD_2="8.3" SE="2.9960416659586695" STUDY_ID="STD-Blume-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="17.351706738574507"/>
<CONT_DATA CI_END="30.721029053515764" CI_START="-2.721029053515764" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="48.4" MEAN_2="34.4" MODIFIED="2008-05-20 16:08:14 +0100" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="25.7" SD_2="23.3" SE="8.531294036731852" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="2.139971925000481"/>
<CONT_DATA CI_END="31.89747452386768" CI_START="-1.6974745238676778" EFFECT_SIZE="15.1" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="12.9" MODIFIED="2008-05-20 16:09:37 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SD_1="24.3" SD_2="8.4" SE="8.570297544426332" STUDY_ID="STD-Natali-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="2.120538181239578"/>
<CONT_DATA CI_END="8.031700006085128" CI_START="-0.6317000060851283" EFFECT_SIZE="3.6999999999999993" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="22.3" MODIFIED="2008-05-20 16:54:41 +0100" MODIFIED_BY="[Empty name]" ORDER="27" SD_1="10.9" SD_2="11.07" SE="2.2100916344652375" STUDY_ID="STD-Peters-1998" TOTAL_1="47" TOTAL_2="52" WEIGHT="31.887269716844145"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="19.33883355428035" CI_END="5.355269382417593" CI_START="-2.625854417679956" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="1.364707482368819" ESTIMABLE="YES" I2="63.803401170229016" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2008-06-19 09:47:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.007189636597639382" P_Q="1.0" P_Z="0.50268192433224" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="17.80917166812058" TOTALS="YES" TOTAL_1="178" TOTAL_2="161" UNITS="" WEIGHT="99.99999999999999" Z="0.6702759114806675">
<NAME>Absolute claudication distance (expressed as kilocalories) after 12 to 16 weeks</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.219159057022864" CI_START="-4.219159057022864" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="23.3" MEAN_2="19.8" MODIFIED="2008-05-20 16:21:51 +0100" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="19.8" SD_2="15.2" SE="3.938418827034887" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="35" WEIGHT="12.441215974188356"/>
<CONT_DATA CI_END="6.183421399390084" CI_START="-2.1834213993900837" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="22.0" MODIFIED="2008-05-20 16:22:36 +0100" MODIFIED_BY="[Empty name]" ORDER="7" SD_1="9.4" SD_2="6.5" SE="2.1344378939553876" STUDY_ID="STD-Blume-1996" TOTAL_1="29" TOTAL_2="28" WEIGHT="18.53544774477416"/>
<CONT_DATA CI_END="7.792641472051844" CI_START="1.4073585279481584" EFFECT_SIZE="4.600000000000001" ESTIMABLE="YES" MEAN_1="18.6" MEAN_2="14.0" MODIFIED="2008-05-28 08:45:16 +0100" MODIFIED_BY="[Empty name]" ORDER="8" SD_1="5.3" SD_2="5.0" SE="1.6289286421765865" STUDY_ID="STD-Blume-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="20.258697852333746"/>
<CONT_DATA CI_END="20.9399639653973" CI_START="-6.9399639653973075" EFFECT_SIZE="6.9999999999999964" ESTIMABLE="YES" MEAN_1="37.3" MEAN_2="30.3" MODIFIED="2008-05-20 16:23:53 +0100" MODIFIED_BY="[Empty name]" ORDER="9" SD_1="22.1" SD_2="18.7" SE="7.112357204190465" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="6.0610638459564425"/>
<CONT_DATA CI_END="6.83057050996219" CI_START="-4.83057050996219" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="25.4" MEAN_2="24.4" MODIFIED="2008-05-20 16:24:25 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="7.4" SD_2="10.7" SE="2.974835535730751" STUDY_ID="STD-Diehm-1990" TOTAL_1="22" TOTAL_2="18" WEIGHT="15.55002278316155"/>
<CONT_DATA CI_END="12.438071813664346" CI_START="-13.438071813664346" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="23.8" MEAN_2="24.3" MODIFIED="2008-05-28 09:03:00 +0100" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="13.7" SD_2="14.3" SE="6.601178345989112" STUDY_ID="STD-Drabaek-1996" TOTAL_1="9" TOTAL_2="9" WEIGHT="6.753230780453765"/>
<CONT_DATA CI_END="24.1644118130569" CI_START="-3.7644118130569044" EFFECT_SIZE="10.2" ESTIMABLE="YES" MEAN_1="33.4" MEAN_2="23.2" MODIFIED="2008-05-20 16:28:15 +0100" MODIFIED_BY="[Empty name]" ORDER="12" SD_1="33.9" SD_2="16.2" SE="7.124830825059236" STUDY_ID="STD-Gardner-2008" TOTAL_1="28" TOTAL_2="27" WEIGHT="6.045366856795287"/>
<CONT_DATA CI_END="-4.179170728085825" CI_START="-17.220829271914173" EFFECT_SIZE="-10.7" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="23.5" MODIFIED="2008-05-20 16:29:38 +0100" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="6.1" SD_2="7.6" SE="3.327014844838805" STUDY_ID="STD-Wang-2007" TOTAL_1="8" TOTAL_2="9" WEIGHT="14.354954162336695"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.194406312191278" CI_END="4.994931933162338" CI_START="-0.6161965740955071" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1893676795334156" ESTIMABLE="YES" I2="35.42561145645941" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-06-19 09:47:26 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.185092875125341" P_Q="1.0" P_Z="0.12614307534007219" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="3.4248967107471886" TOTALS="YES" TOTAL_1="124" TOTAL_2="112" UNITS="" WEIGHT="100.0" Z="1.529489761373715">
<NAME>Absolute claudication distance (expressed as kilocalories) after 6 to 8 weeks</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.864160128885022" CI_START="-6.26416012888502" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="15.8" MEAN_2="17.5" MODIFIED="2008-05-20 16:35:10 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="9.3" SD_2="11.0" SE="2.3286959173161006" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="35" WEIGHT="23.158627569908553"/>
<CONT_DATA CI_END="5.123397966882916" CI_START="-2.323397966882918" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="22.4" MEAN_2="21.0" MODIFIED="2008-05-20 16:35:39 +0100" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="7.9" SD_2="6.5" SE="1.899727748189561" STUDY_ID="STD-Blume-1996" TOTAL_1="29" TOTAL_2="29" WEIGHT="29.130665028812732"/>
<CONT_DATA CI_END="6.909922624296948" CI_START="0.6900773757030532" EFFECT_SIZE="3.8000000000000007" ESTIMABLE="YES" MEAN_1="17.5" MEAN_2="13.7" MODIFIED="2008-05-28 08:45:57 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="6.5" SD_2="3.1" SE="1.5867243729107372" STUDY_ID="STD-Blume-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="34.48009231540376"/>
<CONT_DATA CI_END="14.495513603345914" CI_START="-9.895513603345913" EFFECT_SIZE="2.3000000000000007" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="25.7" MODIFIED="2008-05-20 16:37:12 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="17.5" SD_2="18.2" SE="6.222315154534761" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="4.862146685009057"/>
<CONT_DATA CI_END="17.994505142797923" CI_START="0.005494857202076986" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="25.6" MEAN_2="16.6" MODIFIED="2008-05-28 09:29:58 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SD_1="11.7" SD_2="11.7" SE="4.589117562233506" STUDY_ID="STD-Salz-1980" TOTAL_1="13" TOTAL_2="13" WEIGHT="8.368468400865906"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="90.02981344605968" CI_END="4.610104349583377" CI_START="-0.9220843867288786" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="1.844009981427249" ESTIMABLE="YES" I2="86.67108201086114" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2008-06-19 09:48:16 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="4.907185768843192E-14" P_Q="1.0" P_Z="0.19134684618865214" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="20.474609411798358" TOTALS="YES" TOTAL_1="373" TOTAL_2="350" UNITS="" WEIGHT="99.99999999999999" Z="1.3066051514139034">
<NAME>Initial claudication distance (expressed as kilocalories) at the end of the study</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.051244325072017" CI_START="-3.6512443250720183" EFFECT_SIZE="1.6999999999999993" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="12.3" MODIFIED="2008-05-21 10:25:26 +0100" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="13.2" SD_2="10.9" SE="2.7302768659434307" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="34" WEIGHT="7.131519720687758"/>
<CONT_DATA CI_END="7.674804246028188" CI_START="1.5251957539718148" EFFECT_SIZE="4.600000000000001" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="17.7" MODIFIED="2008-05-21 10:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="7.0" SD_2="4.3" SE="1.568806503732645" STUDY_ID="STD-Blume-1996" TOTAL_1="28" TOTAL_2="26" WEIGHT="8.684095796580403"/>
<CONT_DATA CI_END="10.370513610973212" CI_START="1.629486389026784" EFFECT_SIZE="5.999999999999998" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="11.4" MODIFIED="2008-05-28 08:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="8.2" SD_2="5.8" SE="2.2298948579908955" STUDY_ID="STD-Blume-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="7.827093503544683"/>
<CONT_DATA CI_END="16.479142156069834" CI_START="-0.0791421560698371" EFFECT_SIZE="8.2" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="18.8" MODIFIED="2008-05-21 10:26:52 +0100" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="11.0" SD_2="13.1" SE="4.224129739819023" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="5.198000454499382"/>
<CONT_DATA CI_END="5.543456163821135" CI_START="-2.143456163821137" EFFECT_SIZE="1.6999999999999993" ESTIMABLE="YES" MEAN_1="18.4" MEAN_2="16.7" MODIFIED="2008-05-21 10:27:19 +0100" MODIFIED_BY="[Empty name]" ORDER="75" SD_1="5.6" SD_2="6.6" SE="1.9609830558815509" STUDY_ID="STD-Diehm-1990" TOTAL_1="22" TOTAL_2="18" WEIGHT="8.189796114427825"/>
<CONT_DATA CI_END="4.558494047931823" CI_START="-4.958494047931825" EFFECT_SIZE="-0.20000000000000107" ESTIMABLE="YES" MEAN_1="14.1" MEAN_2="14.3" MODIFIED="2008-05-28 09:04:11 +0100" MODIFIED_BY="[Empty name]" ORDER="76" SD_1="5.1" SD_2="5.2" SE="2.4278476979506856" STUDY_ID="STD-Drabaek-1996" TOTAL_1="9" TOTAL_2="9" WEIGHT="7.553413421111108"/>
<CONT_DATA CI_END="3.2381798317019697" CI_START="-2.438179831701969" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="8.5" MODIFIED="2008-05-21 10:28:17 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="4.8" SD_2="6.1" SE="1.448077543306494" STUDY_ID="STD-Gardner-2008" TOTAL_1="30" TOTAL_2="28" WEIGHT="8.824226574536276"/>
<CONT_DATA CI_END="7.804883240385936" CI_START="-3.604883240385937" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="10.0" MODIFIED="2008-05-21 10:28:52 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="4.3" SD_2="7.6" SE="2.91070819942883" STUDY_ID="STD-Natali-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="6.880765667827299"/>
<CONT_DATA CI_END="6.404826361913447" CI_START="-0.20482636191344428" EFFECT_SIZE="3.1000000000000014" ESTIMABLE="YES" MEAN_1="19.5" MEAN_2="16.4" MODIFIED="2008-05-21 10:29:20 +0100" MODIFIED_BY="[Empty name]" ORDER="79" SD_1="4.5" SD_2="11.2" SE="1.6861668826475864" STUDY_ID="STD-Peters-1998" TOTAL_1="47" TOTAL_2="52" WEIGHT="8.54182801138029"/>
<CONT_DATA CI_END="15.027399354017863" CI_START="3.5726006459821384" EFFECT_SIZE="9.3" ESTIMABLE="YES" MEAN_1="20.3" MEAN_2="11.0" MODIFIED="2008-05-21 10:29:49 +0100" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="7.4" SD_2="7.5" SE="2.922196223601483" STUDY_ID="STD-Salz-1980" TOTAL_1="13" TOTAL_2="13" WEIGHT="6.864874282652822"/>
<CONT_DATA CI_END="-3.811893821161061" CI_START="-6.388106178838935" EFFECT_SIZE="-5.099999999999998" ESTIMABLE="YES" MEAN_1="17.8" MEAN_2="22.9" MODIFIED="2008-05-21 10:30:18 +0100" MODIFIED_BY="[Empty name]" ORDER="81" SD_1="4.6" SD_2="4.8" SE="0.6572091063914205" STUDY_ID="STD-Schoop-1997" TOTAL_1="105" TOTAL_2="100" WEIGHT="9.526991548106592"/>
<CONT_DATA CI_END="4.906664130234121" CI_START="-8.306664130234124" EFFECT_SIZE="-1.700000000000001" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="14.9" MODIFIED="2008-05-21 10:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="82" SD_1="10.0" SD_2="10.4" SE="3.3708089446268636" STUDY_ID="STD-Thomson-1990" TOTAL_1="20" TOTAL_2="17" WEIGHT="6.256135968359275"/>
<CONT_DATA CI_END="1.137378677378953" CI_START="-5.537378677378953" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="8.0" MODIFIED="2008-05-21 10:31:18 +0100" MODIFIED_BY="[Empty name]" ORDER="83" SD_1="2.6" SD_2="4.3" SE="1.7027755120521448" STUDY_ID="STD-Wang-2007" TOTAL_1="8" TOTAL_2="9" WEIGHT="8.521258936286289"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="71.67423373124957" CI_END="6.360493945234772" CI_START="-2.0621814546417645" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="2.149156245296504" ESTIMABLE="YES" I2="90.23358934502562" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2008-06-19 09:48:29 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="6.776801342311956E-13" P_Q="1.0" P_Z="0.31720353235393783" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="30.645700555757614" TOTALS="YES" TOTAL_1="291" TOTAL_2="273" UNITS="" WEIGHT="99.99999999999999" Z="1.0002211026658403">
<NAME>Initial claudication distance (expressed as kilocalories) after 24 weeks</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.1297468379086" CI_START="-3.5297468379085988" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="12.2" MODIFIED="2008-05-20 16:42:49 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="13.1" SD_2="10.9" SE="2.7193085587025894" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="34" WEIGHT="12.136670711132115"/>
<CONT_DATA CI_END="7.674804246028188" CI_START="1.5251957539718148" EFFECT_SIZE="4.600000000000001" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="17.7" MODIFIED="2008-05-20 16:43:25 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="7.0" SD_2="4.3" SE="1.568806503732645" STUDY_ID="STD-Blume-1996" TOTAL_1="28" TOTAL_2="26" WEIGHT="13.945241362330755"/>
<CONT_DATA CI_END="10.370513610973212" CI_START="1.629486389026784" EFFECT_SIZE="5.999999999999998" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="11.4" MODIFIED="2008-05-28 08:46:57 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="8.2" SD_2="5.8" SE="2.2298948579908955" STUDY_ID="STD-Blume-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="12.962023952671172"/>
<CONT_DATA CI_END="16.479142156069834" CI_START="-0.0791421560698371" EFFECT_SIZE="8.2" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="18.8" MODIFIED="2008-05-20 16:44:40 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="11.0" SD_2="13.1" SE="4.224129739819023" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="9.521403537499674"/>
<CONT_DATA CI_END="7.804883240385936" CI_START="-3.604883240385937" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="10.0" MODIFIED="2008-05-20 16:45:57 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="4.3" SD_2="7.6" SE="2.91070819942883" STUDY_ID="STD-Natali-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="11.802341295128462"/>
<CONT_DATA CI_END="6.404826361913447" CI_START="-0.20482636191344428" EFFECT_SIZE="3.1000000000000014" ESTIMABLE="YES" MEAN_1="19.5" MEAN_2="16.4" MODIFIED="2008-05-20 16:47:00 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="4.5" SD_2="11.2" SE="1.6861668826475864" STUDY_ID="STD-Peters-1998" TOTAL_1="47" TOTAL_2="52" WEIGHT="13.786169038555755"/>
<CONT_DATA CI_END="-3.811893821161061" CI_START="-6.388106178838935" EFFECT_SIZE="-5.099999999999998" ESTIMABLE="YES" MEAN_1="17.8" MEAN_2="22.9" MODIFIED="2008-05-20 16:48:16 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="4.6" SD_2="4.8" SE="0.6572091063914205" STUDY_ID="STD-Schoop-1997" TOTAL_1="105" TOTAL_2="100" WEIGHT="14.855803325107763"/>
<CONT_DATA CI_END="4.906664130234121" CI_START="-8.306664130234124" EFFECT_SIZE="-1.700000000000001" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="14.9" MODIFIED="2008-05-20 16:49:41 +0100" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="10.0" SD_2="10.4" SE="3.3708089446268636" STUDY_ID="STD-Thomson-1990" TOTAL_1="20" TOTAL_2="17" WEIGHT="10.990346777574286"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.240051331946956" CI_END="3.118971243914486" CI_START="-0.042438282341833" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5382664807863267" ESTIMABLE="YES" I2="43.82042723362706" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2008-06-19 09:48:45 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.07571921778684954" P_Q="1.0" P_Z="0.05647612510906655" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2.3809043799440746" TOTALS="YES" TOTAL_1="227" TOTAL_2="214" UNITS="" WEIGHT="100.00000000000003" Z="1.9073434655817074">
<NAME>Initial claudication distance (expressed as kilocalories) after 12 to 16 weeks</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.708300078390649" CI_START="-3.1083000783906476" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="10.5" MODIFIED="2008-05-21 09:42:45 +0100" MODIFIED_BY="[Empty name]" ORDER="38" SD_1="14.7" SD_2="6.9" SE="2.5042807506192424" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="35" WEIGHT="7.5174828253931825"/>
<CONT_DATA CI_END="7.7796800412716" CI_START="1.0203199587284044" EFFECT_SIZE="4.400000000000002" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="17.7" MODIFIED="2008-05-21 09:43:21 +0100" MODIFIED_BY="[Empty name]" ORDER="39" SD_1="7.7" SD_2="5.1" SE="1.7243582371564388" STUDY_ID="STD-Blume-1996" TOTAL_1="29" TOTAL_2="28" WEIGHT="12.147904432550689"/>
<CONT_DATA CI_END="8.5407722904887" CI_START="1.6592277095113017" EFFECT_SIZE="5.100000000000001" ESTIMABLE="YES" MEAN_1="15.8" MEAN_2="10.7" MODIFIED="2008-05-28 08:47:42 +0100" MODIFIED_BY="[Empty name]" ORDER="40" SD_1="5.7" SD_2="5.4" SE="1.755528324820799" STUDY_ID="STD-Blume-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="11.906697135340945"/>
<CONT_DATA CI_END="4.978981961597383" CI_START="-9.978981961597384" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="18.8" MODIFIED="2008-05-21 09:44:40 +0100" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="6.5" SD_2="13.9" SE="3.81587724090373" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="3.8392393567287515"/>
<CONT_DATA CI_END="5.543456163821135" CI_START="-2.143456163821137" EFFECT_SIZE="1.6999999999999993" ESTIMABLE="YES" MEAN_1="18.4" MEAN_2="16.7" MODIFIED="2008-05-21 09:45:12 +0100" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="5.6" SD_2="6.6" SE="1.9609830558815509" STUDY_ID="STD-Diehm-1990" TOTAL_1="22" TOTAL_2="18" WEIGHT="10.446509159852145"/>
<CONT_DATA CI_END="4.558494047931823" CI_START="-4.958494047931825" EFFECT_SIZE="-0.20000000000000107" ESTIMABLE="YES" MEAN_1="14.1" MEAN_2="14.3" MODIFIED="2008-05-28 09:04:59 +0100" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="5.1" SD_2="5.2" SE="2.4278476979506856" STUDY_ID="STD-Drabaek-1996" TOTAL_1="9" TOTAL_2="9" WEIGHT="7.859936411986843"/>
<CONT_DATA CI_END="3.2381798317019697" CI_START="-2.438179831701969" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="8.5" MODIFIED="2008-05-21 09:46:32 +0100" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="4.8" SD_2="6.1" SE="1.448077543306494" STUDY_ID="STD-Gardner-2008" TOTAL_1="30" TOTAL_2="28" WEIGHT="14.525712828738994"/>
<CONT_DATA CI_END="4.0255917748102465" CI_START="0.17440822518974897" EFFECT_SIZE="2.099999999999998" ESTIMABLE="YES" MEAN_1="17.9" MEAN_2="15.8" MODIFIED="2008-05-21 09:47:22 +0100" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="4.0" SD_2="5.7" SE="0.9824628360516168" STUDY_ID="STD-Peters-1998" TOTAL_1="47" TOTAL_2="52" WEIGHT="19.438446125380626"/>
<CONT_DATA CI_END="1.137378677378953" CI_START="-5.537378677378953" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="8.0" MODIFIED="2008-05-21 09:48:05 +0100" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="2.6" SD_2="4.3" SE="1.7027755120521448" STUDY_ID="STD-Wang-2007" TOTAL_1="8" TOTAL_2="9" WEIGHT="12.318071724027837"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.667755040938552" CI_END="4.685738383292152" CI_START="0.7459856518418846" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="2.7158620175670185" ESTIMABLE="YES" I2="60.5297072461424" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-06-19 09:49:03 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.026699411699430797" P_Q="1.0" P_Z="0.006888317412943378" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="3.1672954843751424" TOTALS="YES" TOTAL_1="171" TOTAL_2="164" UNITS="" WEIGHT="99.99999999999999" Z="2.70219585047521">
<NAME>Initial claudication distance (expresses as kilocalories) after 6 to 8 weeks</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0838258640846585" CI_START="-3.0838258640846585" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="9.3" MODIFIED="2008-05-21 10:34:26 +0100" MODIFIED_BY="[Empty name]" ORDER="84" SD_1="6.2" SD_2="5.5" SE="1.3183027262059646" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="35" WEIGHT="20.593183183284978"/>
<CONT_DATA CI_END="6.558666777623856" CI_START="-0.1586667776238504" EFFECT_SIZE="3.200000000000003" ESTIMABLE="YES" MEAN_1="19.6" MEAN_2="16.4" MODIFIED="2008-05-21 10:34:55 +0100" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="8.0" SD_2="4.6" SE="1.713636987269454" STUDY_ID="STD-Blume-1996" TOTAL_1="29" TOTAL_2="29" WEIGHT="16.549241873775667"/>
<CONT_DATA CI_END="6.321977500559065" CI_START="1.4780224994409363" EFFECT_SIZE="3.9000000000000004" ESTIMABLE="YES" MEAN_1="14.3" MEAN_2="10.4" MODIFIED="2008-05-28 08:48:13 +0100" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="4.9" SD_2="2.7" SE="1.2357255131539728" STUDY_ID="STD-Blume-1998" TOTAL_1="21" TOTAL_2="19" WEIGHT="21.51838686655238"/>
<CONT_DATA CI_END="10.676195884309223" CI_START="-4.876195884309226" EFFECT_SIZE="2.8999999999999986" ESTIMABLE="YES" MEAN_1="18.4" MEAN_2="15.5" MODIFIED="2008-05-21 10:35:58 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="8.6" SD_2="13.5" SE="3.9675197838566754" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="5.342253337471035"/>
<CONT_DATA CI_END="3.218301437770365" CI_START="0.3816985622296365" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="16.6" MEAN_2="14.8" MODIFIED="2008-05-21 10:36:41 +0100" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="3.4" SD_2="3.8" SE="0.7236364795260244" STUDY_ID="STD-Peters-1998" TOTAL_1="47" TOTAL_2="52" WEIGHT="27.36806895705016"/>
<CONT_DATA CI_END="15.027399354017863" CI_START="3.5726006459821384" EFFECT_SIZE="9.3" ESTIMABLE="YES" MEAN_1="20.3" MEAN_2="11.0" MODIFIED="2008-05-21 10:37:13 +0100" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="7.4" SD_2="7.5" SE="2.922196223601483" STUDY_ID="STD-Salz-1980" TOTAL_1="13" TOTAL_2="13" WEIGHT="8.628865781865764"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.4583598864101" CI_END="0.14787529062685853" CI_START="-0.5780204816480733" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2150725955106074" ESTIMABLE="YES" I2="51.839567529711886" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2008-06-19 09:49:15 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.05249060742417844" P_Q="1.0" P_Z="0.24547159922175077" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.1192330920065469" TOTALS="YES" TOTAL_1="144" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="1.1614189181492738">
<NAME>Ankle brachial index and ankle pressure at the end of study</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8347513492641966" CI_START="-0.06165346356877166" EFFECT_SIZE="0.38654894284771246" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="78.6" MODIFIED="2008-05-22 12:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="23.9" SD_2="20.7" SE="0.22867889917970305" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="35" WEIGHT="19.99215164025969"/>
<CONT_DATA CI_END="0.07307145024421835" CI_START="-1.330018869097648" EFFECT_SIZE="-0.6284737094267148" ESTIMABLE="YES" MEAN_1="77.2" MEAN_2="93.3" MODIFIED="2008-05-22 12:14:40 +0100" MODIFIED_BY="[Empty name]" ORDER="69" SD_1="21.8" SD_2="28.0" SE="0.35793778110446506" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="13.863598542382151"/>
<CONT_DATA CI_END="0.046557211626561346" CI_START="-1.3599459328919012" EFFECT_SIZE="-0.65669436063267" ESTIMABLE="YES" MEAN_1="79.7" MEAN_2="97.3" MODIFIED="2008-05-22 12:14:08 +0100" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="21.8" SD_2="30.1" SE="0.35880841577008044" STUDY_ID="STD-Bulling-1991" TOTAL_1="17" TOTAL_2="16" WEIGHT="13.828711297355882"/>
<CONT_DATA CI_END="0.7536827542151232" CI_START="-1.098580834377098" EFFECT_SIZE="-0.17244904008098735" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.57" MODIFIED="2008-05-22 12:20:05 +0100" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="0.2" SD_2="0.24" SE="0.47252490433565103" STUDY_ID="STD-Drabaek-1996" TOTAL_1="9" TOTAL_2="9" WEIGHT="10.011875874262822"/>
<CONT_DATA CI_END="0.6430669805394262" CI_START="-0.396565546300119" EFFECT_SIZE="0.12325071711965366" ESTIMABLE="YES" MEAN_1="0.79" MEAN_2="0.76" MODIFIED="2008-05-22 12:21:02 +0100" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="0.28" SD_2="0.19" SE="0.2652172527250587" STUDY_ID="STD-Gardner-2008" TOTAL_1="29" TOTAL_2="28" WEIGHT="18.08902792171026"/>
<CONT_DATA CI_END="0.02455461840607931" CI_START="-1.304881856261772" EFFECT_SIZE="-0.6401636189278465" ESTIMABLE="YES" MEAN_1="90.5" MEAN_2="103.5" MODIFIED="2008-05-22 12:23:52 +0100" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="21.1" SD_2="18.3" SE="0.3391481897510048" STUDY_ID="STD-Thomson-1990" TOTAL_1="20" TOTAL_2="17" WEIGHT="14.638758888832191"/>
<CONT_DATA CI_END="0.6892528948166983" CI_START="-1.2266047076310833" EFFECT_SIZE="-0.26867590640719247" ESTIMABLE="YES" MEAN_1="0.62" MEAN_2="0.67" MODIFIED="2008-05-22 12:37:28 +0100" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="0.16" SD_2="0.19" SE="0.488748165160131" STUDY_ID="STD-Wang-2007" TOTAL_1="8" TOTAL_2="9" WEIGHT="9.57587583519701"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="68.7435773041988" CI_END="1.6976665094644747" CI_START="-0.9402251245367543" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.37872069246386014" ESTIMABLE="YES" I2="94.1812745904981" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2008-06-19 09:46:03 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="4.1744385725905886E-14" P_Q="1.0" P_Z="0.5735833658251996" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2.1110083969321267" TOTALS="YES" TOTAL_1="111" TOTAL_2="97" UNITS="" WEIGHT="99.99999999999999" Z="0.5627819640970817">
<NAME>Quality of life (expressed as a Visual Analoque Scale for complaints)</NAME>
<GROUP_LABEL_1>Ginkgo biloba</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ginkgo biloba</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.19937006621058406" CI_START="-1.1116356903319136" EFFECT_SIZE="-0.6555028782712488" ESTIMABLE="YES" MEAN_1="43.3" MEAN_2="53.7" MODIFIED="2008-06-06 13:00:27 +0100" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="17.9" SD_2="12.4" SE="0.2327250988582352" STUDY_ID="STD-Bauer-1984" TOTAL_1="44" TOTAL_2="35" WEIGHT="20.915384522113715"/>
<CONT_DATA CI_END="4.142335786888408" CI_START="2.464645420949198" EFFECT_SIZE="3.303490603918803" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="0.0" MODIFIED="2008-06-10 09:57:34 +0100" MODIFIED_BY="[Empty name]" ORDER="75" SD_1="1.1" SD_2="0.5" SE="0.42799010062751586" STUDY_ID="STD-Blume-1996" TOTAL_1="28" TOTAL_2="26" WEIGHT="19.739197647518537"/>
<CONT_DATA CI_END="0.8700614258608004" CI_START="-0.9782428875358369" EFFECT_SIZE="-0.054090730837518294" ESTIMABLE="YES" MEAN_1="54.0" MEAN_2="55.0" MODIFIED="2008-06-06 13:06:54 +0100" MODIFIED_BY="[Empty name]" ORDER="76" SD_1="18.1" SD_2="17.1" SE="0.47151486659342356" STUDY_ID="STD-Drabaek-1996" TOTAL_1="9" TOTAL_2="9" WEIGHT="19.407996011983652"/>
<CONT_DATA CI_END="0.43857023898155273" CI_START="-1.3421046530129108" EFFECT_SIZE="-0.451767207015679" ESTIMABLE="YES" MEAN_1="21.9" MEAN_2="29.4" MODIFIED="2008-06-06 13:04:31 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="15.9" SD_2="15.9" SE="0.45426214615171495" STUDY_ID="STD-Mouren-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="19.54176353911115"/>
<CONT_DATA CI_END="0.46431330330440357" CI_START="-0.8318394976313701" EFFECT_SIZE="-0.18376309716348327" ESTIMABLE="YES" MEAN_1="41.3" MEAN_2="46.8" MODIFIED="2008-06-06 13:05:22 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="28.4" SD_2="30.3" SE="0.33065730063400695" STUDY_ID="STD-Thomson-1990" TOTAL_1="20" TOTAL_2="17" WEIGHT="20.395658279272933"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-05-07 13:59:58 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-05-07 13:59:58 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgments about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAMcAAAK+CAIAAACZ1Z2xAAAYqUlEQVR42u2dMW4cxxKGFzBgOGDA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-05-07 13:59:58 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgments about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAACcCAMAAACa91sKAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-07-18 14:52:31 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.1 Absolute claudication distance (expressed as kilocalories) at the end of the study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwsAAAEgCAMAAADMjB9UAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-07-18 14:52:29 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.2 Absolute claudication distance (expressed as kilocalories) after 24 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwwAAADQCAMAAACdtRaAAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2008-07-18 14:53:30 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.3 Absolute claudication distance (expressed as kilocalories) after 12 to 16 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwsAAADwCAMAAAB4xQjPAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2008-07-18 14:53:45 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.04" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.4 Absolute claudication distance (expressed as kilocalories) after 6 to 8 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwUAAADACAMAAABidj/RAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2008-07-18 14:54:03 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.05" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.5 Initial claudication distance (expressed as kilocalories) at the end of the study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwUAAAFACAMAAADasSC9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAzU0lEQVR42u19fXBdx3XfAfC+HwhgHwFLTCyHFBl5JrZVm6JI4oNW
DSpWFKVVx5adjl27Gv8hJ7XH6kw0qcdtR3Y7ja2mzsQzbuy47ciO4kw8teJaDm3ZFjGWANAiTFFt
7DqVAxCUZJGSAL4FSAAPwAOI7v3ee+/eu3vfu/fdB+D8JPDdd+/ePWc/zu7Zfefs6SCAQOxydGIV
IFAKsAoQKAVYBYhdj65iu3E0/g3IFib/2+iBWfOGc+WGeZ99yNOqY/TAgV+66QuptgiMm190jb94
IJioxu9dV1Y1vvre9VK+zP7qbdCKOuP9x8MZv5TtqWmMV7Y6cz3sbwPnAhMDd3a8tnDsDhgbU3xB
OaEqxuqFY+9qnwrZgH8q4fe1Z95R06phZe3VX9bYX5sw/jRIevXY5a63j2uMLw29+srS0PIrqBFZ
eH24VCmOsSFilP1PyvmadrN+d75eL+f72E3Yyud6zLR9+XJdS6ihJ5fvse8NlHO5wnjDPMwa7Vcv
5/LFcaj25HMsz+pDufxWld0m+VLdoZc0zgxA/Qz7rGrlrlo8jY7WioWKmaRSggF2Jz8C9+0bhvsq
VY23KrtTLoB9raevPpTPFaesvBJm/D2woTNu1Fu9yEhXuDbVGH8SfovdyTHGbxyBuyomX6OjpRLY
13p61gZZvg12uhR8FF5wvlwvDT/IPq7sGVvKZo6VP6P19pOnykd6jce0dCxjCcSRclG/rd9bml9/
cejOJrjY0v7p/d760uBjcODID5eP9cKB892lk/vZ7c3y8YxDL2k8sgkbj7DP/SdLi0cOWDwB3NA9
tGKleQE+wP5dY6Or9scYLpePaJx+75Jzrac/cL784uAdVl7JIvNh+IDWOma99VTXlgc1jq8X9TbV
8RZ9uFlnTGt/Dl9XFp1rPf3+I6f6jDb4od4GO10KvgbagDFqDspz7DvA+4dKWcjD9CC7vh0Oz8Cq
KQUz7K6BGsxcgCPWvdpNPR8xenIjqN4MOe1z5b09PYz+Grw1O7bCaE7PaA0GF6c1Cha9pNEzODDU
o5d7psZYWenUeQJ4ag6uW2kq8FX+lVWYmYZhdvHWinOtp2dl2MfmWTOvZJH9ef90VudGrzfWJHt0
jmfndf5Nxl2NZPNVyzrXevp1ODxntMFb9TaIGR3t9qtZfvibTAxgzPjfuJrs6KhBbkT/pn9MaDWh
P55cMxLmh/Xb5j3yjqnCrdDQgoHJ3ySsbmRZTiyXf/igwQYDm7fZ0r2uU5hYN+klvsiEn77t3m//
9G1audnXiXWOJ4Mv7d/qfXrJrZv5YT2p/tx8za5KpyjJMj8Kn/vk1NHv32UyPl7vO3y29DY/41b7
6V85ZkMYH6/v/LlgFd7su/dUbnAcOqBa1RlmHx3moM2riOxLp3VvCV76ReOr47W1Dm0Qg2V4SZtq
8qCT6YBvjo3VHaomvaQxN/mHk3N6uRn5dYsnN95szF0O9KRgc23390NGUTpdNxPC0TPrk1mn3lbg
5Rd8aW6BjLszOny5eTzjaYOdLgWvTq5Uvfr2iSsTv8U64yFNH87B+YNQMO7vP2RrRAU4aOgx+r0u
ePP5OOpGz2USzg+MljQKl9mHTmHNoZc4ssO6SObg5joj3ykoWfXfwff47zqn5g54nrsG+AYc0r6Z
eSW9ohn5zzY3Jbgf3nzQx/gquDbqeb7cPOY8bbDTpWDfnq0bVp993tMTssf6rzy7XIAJuHjus8vP
LRq3v7D84yvWts7h5dvOXbXulSYXn2yeleKZxfdo64DT9yyeXYTZc8v7z/5IW/bdl99w6CWOjDFe
Xjx3W3lqEUoGTy7l44Ynnz/h2uI6vPxrzz5tXF/krtmTc0v7z1618koYD8OnDZp6vQ1O3urd3Bnd
t/G/5/kbPF9uHvk2SIDxjm1jTZcvzO6568c1QCB2rxRUVjeg6+mj2GSIXSwFCERSQGs6BAKlAIFA
KUAgUAoQCE4Kqt353MnyFPS7XQ4smx4BprZO5jQTTnlKKUZHR+vQPxohi/pWLp/7hGZMOZq3zSut
vLiMxkviorAkU5EoWvXDXskVSDBBrv7cBOtQzY3mq1AfLfiem1fuuh8dLY5qtVu3fvfSypor9Qvr
L5jvcj7XU2eZ6EySXB9Ad82qm1y+u95Uw/kZMXieSI7nbL57KlaeeSl47Oie9b899k64dVD15Xed
/Mv1hWMfi4kVqT26G+Rk71rPz5bAslN3oHkcOF4HDx8PzOIu+OsIBK36YZm/2vmOWiDBwPq7AW4Z
geFb2GeNe9EF77s52Mv+3ev8Sj221nN8OVq9PnZsoftIP6vcqTHNCWH5/VDfNHpo/50dr5aPxm0g
ngOty/92Uzy/SeN5bwDPry0cvSOxueAPGdHi2GpWM3TSJI391cvaoFccHbDGr4fymlX96Gi3zlId
foO98RUrNUDv3cU6TJUKfbp3QImNwj35XC9YCUZHH9Vt84VQsEd3YQ3WYX5Mf6Tbqfuh085pxRH7
G5ypwkmdomGDP1XKZUuaY0OllH9UkJ1ZPzrBMogGN93nQK8/My831tl/E/q/RPNZeEiznodq8W7d
bQJqrJw6szx+qFtQrrNPG/OwaZWH1WeRNVC9lCd2ebUaK+X6+vIPjNt8F6dZbd0AuiXGVvZrsNe0
O1kdXqhUx+L+IfKHuimomOf+cJ7zFs91jef1IJ6LcfPcyV8eLo5rDDjGmJljpaom3HV4TLfY6T1f
OqVb1c/pfkFd8I6iq29tPTv4Z3D78b81BvUrL0PvkVPl2/qcBA9qtvliqNij88jCbR+3uuJbRNOI
QVs3XBf7G9Q+CgWtOk0b/DuurK8c15pmc2b494VVddgu7QvwQX8C3eegR68/Oy8em4zLNfa3CXP7
j5zqPq9b+D82+CzVnxZKww+ug8cQ9ujZoXHoH3qW+7FwHDj/iX/dPVSDzPHSpl1enf+Rw9cvTlvl
3dIs0bYY1ZUHmPZ6P9PL1i4YTz4A1xJQsoN4zjOerwXxfF3nefg33Txf13i+ovP8z5PkmZOCq2dg
8GGm93LIw/RPAF5lUvlxfYJbhZkewwBcV8Sf9r5xcQaegAL0GO1a28vS9swAJ7i6bb4YKvboPBbz
8PNbzUVJReRMwNEW+xtUpgeGCdj2+LVzD/WA1jSz+xzTfRDXT0XEk+5zcLtxaeXFYXJwamOCTm5U
Byez69AzbXhJPAEzhgTTOVGeWRhh6XKcLv3w2UWnPLOa10AeZi7y5b24j41A++zy5uDbRa1Ak0uD
x/4AbisXDxRuzukj0zRUklhringuQ60zjOdZg+frbp63JnsGj31G5/kbSfLMSUH20vkzcMylcY1A
hUl0cXLj8saZOV1E2fdNvRfoUn/pOfcblQoT++twNGt2FZb2qItplqAjgJPvs5p7Xadx333svb5b
N/fAiJHLsLCuv/78JBwzzE+rolw52uTW6z/RM3PhdfbfnH7FKJ6Gpx7+UjecMCiOiAhy9RPg9aeX
X4OdFz/ZwehIppIZeRO72oRP3mcNkxW7tgTlvDBRrNYnLjhLkFMT16855dFZHdHocuWt6D3RLgOd
+mj/RCcsr2XvhS/BR9cvrM+vvqhL4CQk4nYp4Hnzhcg8D+g8z90LX06eZ36ntLJw6XlzAJvUNSOm
xerG9NmRXx/RRft+7TunWVQWL51nvX7C6ha66X8XVG3dv8u4NW4lmAougoo9urvL0cvPmZqQx07d
wJ2OJ4LY3yA7mTtj9EDdlP0eGUWufvaAULGzfQ5EeeXYDJdnTb3B/ro0krq3V4fbS8JHMzf0R8NZ
biQplgb3e8ozaWTBldddzKX15Y4up7m/vZId2nfdGLT3JCEFjOf9bp6LQ/s1zwg/z13BPC9ZPGuP
DyXLMycFhdFK5QnWuof0ofVyvz5hHdrPPr4LRw1v4G/AwfNwhnujVvkOe+N+6N+v3zhwkHFZg/MZ
p+V1b4AuGDAS3HkoUCNSsEd3oTg6zkZRvRd77dStitZpa4NHgL9B5kSXTVHLYC2UolU/GkEC84IE
ms9B3nRl8efVxUa61+HvYQi+Y9jLl7W7fwoH9ztpDvlGuu/Cec17wNkYXDizetldnryRxSTnecFv
RRbzlyvDV6CYO3tQr/x/tQGTA3q7/8NEX/WZBOz1s3BE35WweV5kPHfCHj/PORnPAz/Tea45PE8m
wDMnBdfOLuc+PfUj+ObETUAnP6L1r41nl76gNe8EnNmnJZk9t3zPOce++5mp38neObUAg5NLhhbY
tXJmDOiPP0+06UFfB5y7Z/ncAtAz175rkFs6eyWIFak9ukdNnzqZv3p6AQR26g7t5xagPPGrQf4G
f2IIkWmPXz60fzOMoFU/jOCNJ54XiJ3uc7Co19/CpD+veVaLWdh3BibeYtjLa7zDbc/WOq3aAv1d
N946ARNvNWZnS9hGft1dniv55S6nvDz0fMsd+1cYu93ZEyvnmC4+3pmF4qLe8/advn7DZ07Hf3LL
DON5xs9z2cXzSpfTP4J5XvxNh2d9/Nz3VAI8q9iUVuFXhv5uXn2/uHRh+pNnRRvEozAGCDfyxQt7
7jor3U4fuLYaPe/+5VTdMbYPzypSkN/qLEVYkoy/exOypTnh7ynr2O29G0tka0tcWy6Ui/PR8y7P
p3ry4PbhGf0LEAgEIn28N2X6GZwLEOkj5V6IltUIBEoBAoFSgECgFCAQvDkMVVqnUGKmJc6HdTde
WHn68nax4LoKzymASXl2EQkq1Apf11buRKEaKXG/75CyPz1MUq5ROar8UwoEpcC1Upe1A7Ubg/1R
q+FoAqxRz6eYBddVeE5UoUTC7CISVKkV4mVLr025EHje5zghQUwSEVXXU0LT74iLAL3tIQXuscyq
KOub0bAtq7FASuYD4mrbpumEZBe1zESVcOTcXWmFIkO83ygRTyaQ2BSujlHu6lsuN7ux9KXAPdRR
wt8h0XpsEyBBeZMG+3kAkySuXh2xVqwaJhH6JInUgalbaRW+RdPcq7f7+uhYCl0/SApMFZIo9QVT
o0yxEjl1NpYxjRJ/xlLVRMaZstBT7f8YNHTKLTcoAclqg6Q9H1joTZO4cF1ApQ1utBm/PEhOMQpp
QSXCNPL6XZaxWXpJBhFrhUCTdWmOSMS9UCCJTHM7eXXM60CSmiLeBkhMEmiEnZPQHGQZRRKTpjkX
PImkV/rfJ82NKbsZnUq7KjRcISCEJDaqBOZNVdvWzEHGJCVKyo5CCpp8raizRpspya6cC6x1gTHh
Ox/+xjRvprkuIPZOFo1jjWdmwrILKpRDUFLsCLVC3QtXxZ175y0fKR+Tzg0vpbQbsI2A/gU7BJQ0
8ThtRWk0ZR9EtKDYMWKQyqs7d3WM2IYgTTze9foAzgUIBEoBAoFSgECgFCAQIv8CxZ9q3S4GcW08
+7KTZyzzi5Bx6FhBE0l2NJJ/QWgqzjHArHV1mx5KxHTcWVBweyCAwL/AuIH+Bd69AoV2ELkY0JjM
snzZKWQsMeWXcUg9mQRnR905NkrQnYXjKaDgXyBiw+1j4DV9cXHh8y8wbpC22SrVTv/sTVkKBA2p
DRPU61ZGg3tjs/CZGxOIMjo2wJZTHKpqoqq+K9k89wCRWPGVhgTTSs5LsEElwFDQaWydqVkp4OqM
OhaSYS4GkOa02kxLCro+jcmLQrFKHB1GMTkNJkAEOpe4pqgzV7QFiDUXpMCQyI7IwxqRTc3UkhcS
Z5eOYu2vkmWsJjNUxdE5rEpEBkCR/QvC69zx+ySR300LKXkZqK8LqL8dOZu7BCWYxOdD01RGlETk
iUTiRtW/gCpqiyScV7QfU9eIwqqNJFOd0Z1i5CcGRDPUpIE6nypXlDQiXYoaVzPOHJTEqEvuHHRK
dyKCboUf7BCjPpTqqoGXettfgLaGoIwNpZ0k9CBofF3g9ykMsmSP2VDdMvOXWvtHzlItI6pyHpMk
KxWCArN/df8CNxsiOqr+BQgd6F+wgyD5DSOlyUsB6F+AiFEMWvrablwdI9oejf50iP4F2HcQgFKA
QKAUIBAoBQgEro4dtIV/gdfaH4KN26KGEwj8Tdj3azUNPAeMqBD0xTsQ5+WNJKBwAL2qY0HQMb3e
LNC/wCcF7eBfILDxp8E9LVI4ARpK0XXWXUBK4iOtUEHBWXnrUeJf4CtwgGOBsEUCQjC0m3+BhhQi
GcTpXxDPTEDDZ4CQzhn+OIjt8HPd/VNGlDLEk59SUd1EvSePhxx/31b+BaaSThWbNmEp4KpI1b8g
HvhN2uISOhJ+n8h7sarS17DFnTyOEFEiGup2EIMsJtvyi63/ASMu/4LW26W4KDZ1PmGEdjLHAdXC
UvVyKPgXUPWj6kMcC1REKlWk7XHZhH8BTSochILnbosokoikiZrCbWUm9y8g6tJqfoY7oqJVtaJG
FNYGCfkXeLti8/ELojZ3XNEYohqw0RRWqSgJ5lJEfTZvhX+BryspmNPHKwRBFKOWNOWNFwxc0PS6
IDX/AvX+qxy/IFJ4gzCFRDV+QVCNickR7ueM0J37oNAEARmKHAuiFmG3AP0LdgJok3tA6F+A2Ali
kOLbu2p1jGhfNH4mWYIbHDtidYxAoBQgECgFCARKAQKxG1fHnoP7KQn+RV/kYRD3fhtvAR+YRukg
O7/LQnBhQGQ15/MXUPqdTha/IIp/gcS3IDRFAEvUToT+Bd69Am87hMSd9xiyx7zf5rKAD+lKoBiL
PjCjANP7kBRqBCXWRh5nhXD/AolvgSSFkCXq3CDtt1XaWieDTGiVA+dlYLhjmPUsMq+IuS4VLODV
XAMkLgsqjgW+WVKRoHQSg8jblKTBIaXVJvuR8LhIU6cxlb1BKRA1mfl/CDeJsRg8nqrZ80nMrxs4
e1qZoEpEJ6WSxjakUJnTUSp475hgLmihuEr8Czx16Ku5ZE3qWvnDvmNYE2xiE1F/DrWT9sy3Ev+C
KM4UoleCWGpbc6LWOhk04nfMVSEfwWB7Q8WNOaJJPon0LNS/gKqtnKWvEMG2AhpXN2dBkaiHAd8p
t93M0hBjjforN1Quit3ftQoJ2XwJv52wh0G7NRJNKLOoPkDxeI8qRkHYhXOBuS4IUHF8txN1LYjm
FhDbuiDE9F5ksB9ZMfdnZpczzL/AlzzI3UPVv6Dd1wWtRUcaAxGidVMm+hfEuy5INoYfIj3NEf0L
4tnyQKQG0nyroX8BdiMEoBQgECgFCARKAQKBq2MHtuWkNAx8kgEMAgzhBQlBMZyAjEEPxUBHBOWA
CYr+BV53ABLhFD471kSwmwH3m7S4zmyvEPQv8O4VUKJwlpRdufEHMAgwhA/b2lCLXxCYyksxyBFB
OWCCin+ByB1AEr/AVRcmkyFuBuL4D8R7ZR21nDYWUzmmVyQFeuVYHcYaKowhinIuSUka5arn7e4x
8rNIiJyi3GqTqBCMVj+k0dqhoea/Qi5oRLvUFkBn8nGXQwFJXwo8YxU32NsmlUlyGeEMW37ub4In
gTdAYOgnNYKk8SEgQu1QxR8K3JLj08PSngd0dkbH0ohaIJcCwUBKAifo+CtSxb6F8PbBVOWAaFnA
JLkxgipBaRl8DgMK8QtikCV3DKh2Wg30pkk8I9VAw1o5MfcCt9osGxdJbIOSYgoSrQxKDwmox+mQ
zY1BMuFfFaBBQKgUEOV+k3BFxmAIr3ZShbpikoDIR15P0CA/UO+D8PpDNwMNnSG1q3TSQtKmWIGG
8DQpIWj5+pAkmZur/qi39tDNwD8XcFajCop5kgEMFGz5lc/ip9ahO6HJ5BRjjV8Q0b8gqKf7aFiF
JcJXMH6BGBi/YIegKTcDjF+A2CFikMqrO3x1jNheaMbNAP0LsP8gAKUAgUApQCBQChAIXB07EBnW
Bxzz7LmM09PAZxUfbNsWzRBA4l/gMuUm4QTVShiWiqvrKP4F8jAGvmJQsRGeWRiMX+CVgqjnlEIS
ngY+q3gq39pQPtiQEgWKYeeUylIoEbSr2lN5cv8CeRgDXzE8XFB3YdoifsEifKu3jaRArxyrOVwO
Bv6BhYba5TZhXEwlN/wTUnPWwb63CcgIxjNyUtJEdZEmEzdFPJ7i81o5hVTZyQQ1kNvBwDewhHoa
NDHD+qziFXwWm6s3oixL8RodUFFMgTiypSGtwUU0cQ1yKYBwc0HaGlkmiEPiYpaAZLnAm9Y1ZR8c
qRqjHnSrnI7ICKpRVlXVTBOiaP4FCjpZSGu4vahSRW8bn9AYdj61V4dwexrEMqLFqxOA1A+CuvwV
AvpNnAS9+Ur8C+QTkceMTtQafqUOzchCpcAdr8/6RsTdJH5PgwTs3kmMFGnTBx/SCL6lwswCwhhQ
33I54WrdCZD6F9DAzZugiSKWHiu3e6fR5UqNIpVnoLozm+TikjRQDHkhcS5wnUptT6iUC2nAB/8i
rrk/GU8DNf8CZQVFgS2l+AVqoRVUCPLkFPwL5GEMfPmKqsn3dLcD/Qt2CNC/IE6NCLFdxSCVV3f4
6hixvYD+BTgXIBAoBQgESgECgVKAQMS2OlY45E+QPIk4BkqxAqhaOAE1xqj7MPPQFLKNRwWCjcUv
8IV1CItfIDiOTFCtGL/A+6tZNAM1oVtBPHEMlGIFUDW21RjjHxNZChqhXhQLGNG/wDGVC4xfIPhJ
X1Ct7RC/YPFbbXRar14rxAleYLoZWI4EztBjNtc2GUBIAxIYnpfECJu0bWFJW/DoG8k6bVkl6UuB
XT8e3wJr3nQ5HbRBBSY1hAW7Zsbi0NCY/EUvvZkiPGHa8Qv0Ei+mLZYZUQ/w+Bb49eSQkCjxWKa4
j/ePkjis9ypmQoLdraMce60Yv8Cx6GlB/AKeQPsYl/a2m3+BMfTT0AlMWXWNY10QaKXvjk4USpJE
8hImMWk60dYFEeMXiAyzhb4ElIRVBZpZB2hE4PUtCOkILXIpC5TInXUYe7T4BYIO7qZN7YYMOUgE
HQ6shQk/Swt2QWjgdNCK+guOcKl69H7MjgiJCUG0sSEwrANxpwiIX2DNexi/wDcXWMoqp4W4FRK3
quu2cY/VYl39oH15EjXG5BSVHRoktv9B5CL5FwQtiVTjF1BAzwIH6F+wQ4D+BTFpRIhtLQapvLqD
V8eI7Qf0L8C5AIFAKUAgUAoQCJQCBCKm1TF/Dq/vyn3Iv8+lIL4VlouAmw1x0jjCCQTR9rwfX/yC
5v0LPLz6/QsEXg6iqAkYv0DgXyDZRxAFLIj7aEZQtOVX9C9QT0VDExJpiggEm/Yv8HFCAvPlfk8W
tyBph63SxRR9DDy/HfPDCAUuioFdtTR4SI5nJvBE1FEwriHx0pbOFXERbSZqQRCvREahrayGrDI8
Dt4oBq2dnYKt6QgR+EuRRnWNhnsGaaLTxt0rBSEHmukBpIkeShqj0GamcxYz2m/HaUYxcEsB8doW
h+q1jt1RErUbyeUkGbu6MN6aPbCXz8I6D1bFv0BKl48JQhX8G9oFabpcZkAkBlTSjqaNnTlTpFOb
8oADQp5bM2vICQrjDDQVU8MekqiCR1zbeAy23+rYVUWeq2RU8Wamgqim8SR5lhoiGCk+WwgPJIEi
7BJ0CmZK+WxAk1E0IjVX1LP4W74PQiF+vhT0IUQMcwEfmknfQxMNUIkFLHAak6rpOSouCBE1YUnC
eAg25l9ABWGb3G/48sX4BQpA/4IdAvQviFEjQmxbMUjl1R28OkZsP6B/Ac4FCARKAQKBUoBAoBQg
EDGtjn3WnEEvBfgYxLPI8tr4hzgvUHkSJyENXAf6vQqo+Aw+3vBHEgoBSBT/AiN18v4FAfEP0L/A
u1eg8kOV07NiDlsAIgt+Ep5UYZPDFgCqRpGKCVGXUIUfjArK/gVO6uT9CwLiH5D22CpNz8MgEzji
cO4FZiADtdP7m50JqHi8l84eytNMMEUSypOTkCiRIU0wFSZdio1AIt5PE49b2jlNh8dM4IhD3PEK
FM50jgPSo5hF3Vd6iCMN6W9+nwFvDyNRmyaadkj9B+02Uk+qxIiqGLUQ7x0z54J2iOIRqF8H9ANO
U4jfIIUbeKn8J6FYDouPGM1Kzo+Sfb9t9qPiXxBJhaekuUK2GOl5GGREA4zIoFRkt8VZ3sVsr+5Y
8RF5E5MmOqxoTmi2GKomzu6pVc2/gEhjLbaokDt3dexvRhIy4EZWFGLuScr+BVGFVCFjRcLR6qZJ
JSWaAycGLuDQKd1/oeJ9k8D7sapDSvELJCxEPaNfIb000GsUUWmoWppW2jBwgWQusJQfYwuNBGtE
yfkYxBm/ICpFhfVDuPZhZRWWKqn4Bb4IBa5X5O/vTqB/wQ4B+hckoBEhtp0YpPLqDl4dI7Yf0L8A
5wIEAqUAgUApQCBQChCIuFbHbjsi7xE2kJhLgYcHd95BVFz+AiobgcrxCwJycx/+L/sRA+KPXxDs
OkCB+BwWhN4iFDB+gUQKKAnvAUm5FHj7jyvvQCq8vwCVCRZEiF8QlBtPkDRLsIH4BWGuA8TvsOD2
p/Ay3n7xC7xopbdBJmzQcbxTWlZPEU5uV7fmofKOyyUMKWzoXBGZIImtkgLmcEp8RYuLhWRA3bo6
bRWrGUFt8iFqWuBS0NS8ASAVUhKxcxEFgqG5EsUWbyZ+gYJSKYo50uYGE8Q9F7SMVV4KrAPEpS61
ydalz+k3LmI0zlgjlDRHsKH4BTQsZ+p2WFBkvG3XBK30NhD6HdOAHpmML4G8yzVlIxMho2Y0kqgE
o8cv4E9OFqUj8ombJFgpO2p1DN7wBa1WIxvwIm6RrTxN2JVCtvoibcHuTkSnfJkiu5u0PiTvRkq2
8jEyH2vABBqdKo38NOgRhjsIXhdYU6/XQj7xsAXgt4pX8C9QHHJjYje1+AVBoQkCM/TXT3gWuxfo
X7ATQElzowT6FyB2ghik+PYO04gQ2xVN/niB/gXYhRCAUoBAoBQgECgFCASujjm4zOapmjG+y9Rd
0XhTnq3blp+EchB6oK+bRWEyZY+GBgjGGb+A47+h2AXCFKahAPoXePpfhHMMwWvqHhgjIIIQ2LsW
Uit9/gw4SmQshnVcNY+GiARjj19AAsqlFrtAmMIcblLYKl1M83ReJY2IUu6D8h/UehbYvk3+AEMb
PE+WSFkJMbOMYQZrvOyUxFkz4aETkrLljl5o6nSzdtOIzIpyuZN5hhUqsVxstlojCAFnfEYljicy
1Uq1H9Looqg0+ynFL6CyPt6AapOWJkRSDFYgkQJCXYMJUay2RI/tVbJ0UTuVP0S18rqQ0eZ5UtX9
1OMXEJVjGJ2Vi/gkY+s+GhAFzgWR1gV2h+CiGCQxdwbq4CTaiEYiFkmikjQ56fkDNIT4FxgGhvJ5
wnXOvi1ZrpmESBc/LUJvu0pBQ7XiVqtjq1i1IIPxkPNOBSRpgkGTKqGNCjCR3saBP+rqOEQlkIV/
bKFqGfEEfmWXehoTQUVuaLP8g7qSiu4E6usCl5W7xxDdawGfrJ16LPELJCxSO6Sno0eEZdc0QT5N
BP+CKLEL3BxQqRPCbkdH1KBDWGXth6b9stG/ALEDxCDV13eWRhTnRguilUukJhsN/QuwDyEApQCB
QClAIFAKEAhcHdswdwpIA9tmcUY38J79T+Xn51Lp2aqhDFHPD9/+hH4yCgETwp0tGohf4OHR8uiQ
+BgEmNaif4FYChq3LIkzuoHXdj7cSh+kSeTm/t4gCP6EfjIqARNCnS0aiF/gomtmLvcx8LDgLWRq
/gUW2sLPICB+Aec+Rqgd7cTtV2b/0BlndAPf2f9EnlgCokSxaTKi9CpeM6ShnKWZO5ZdNMaixdLE
XpWcwuPqzdUyKXA5FuiX0IirQUMgiSWWZRLcIUjEzqOmNjUSv4BESSxi3st4Gl2OeOcCkvpvxxkp
myRoaE7W1YBCg15nYdp0Y8NVMiOixxdAKX6BQhejfMgOknIhFdAWFtaZBmtY/DhGV4NWn6tPfQEF
4hMqyYhoFFUSv0C+2UD94c0oabyQu3R1rNRycp9XIIn1z0RzoJ51plraWGegsH5JpJnHXchdhCi/
F1Clx7GMMLTlQuB4D9AIaWNfLCa1CI1eSJwLxPqPxG4+zugGjiE8lesCMocAV0gEucRIyhePotZA
/IIAxUbiYyAaCdC/wAOMX7BD0JSPAfoXIHaIGLSfUrYzV8eI9kUzPgboX4D9BwEoBQgESgECgVKA
QODq2IZzcDuVHrsfe9QCAR1Z/AJFFwRB+oYT0vgIRo9fICyzyL/Ae8Vn6j/5mhL0L8h4m1m+seyz
Lo0hakHwvkXoOaVRztxUdnhoIn6BOsFG4heERyjwny8p8IXwH4mny0pqW6WL0Bb2dJmgunb5EFDL
A00WVSa2qSDq0ZwtHcxIi4sqICxvCBp6EipN25aO2go5u3oc0t2u5X3NKPENOrarQfJGlg2qLy51
IOGGS6bn0FjPOvbrTBzXRDDVpiQNxJ4LCLSZf4FuYEJE0ysXMYO0qJLM2UclrpmKGbay5YxSxAS1
rKgKEdX4BSqDPW/pRLbBgZptcn57JnL7tVjnUNHB1Xpks+sC6nMJkEoTUfA7VohfoDY5eqIcqMXH
QTOyECnwu22Hq5vpqJYtJhs1fgGJXB65f0HIVEAa4ZqiJID79wJTGaIiC3Ta2p5H21AIohrnU4gz
mZo+5N8ECveFiNVTYsfNBe7Z3PnmttVPzkhd4aB95YADMa8L4iHYmH+BU+YgpwlV/wIED2X/Aqy5
9gb6FySwOvZNsygE21sMYlPKdpFG1NwyD9F6oH9BTKtjBAKlAIFAKUAgUAoQCJQCBAKlAIFAKUAg
UAoQCJQCBAKlAIFAKUAgUAoQCJQCBAKlAIFAKUAgUAoQiNTQs4VSgNjlIEsLWygFiF2N/qtXIEUx
4KRgVIfNV4l7oH9UClDvzuW3qjBlpOzN9wFs1cz0xVzuobqWttAmDnwDpXyu1G8Vq17K5coDyTZl
OZcr1qFqEtzK5bur7hRlVpPm/anuk1p9MVS787mtOvTlegG6K6EUykZLTDFC3dq79fyo1XT6p0OT
XZ3cmmKtmM99om6/b6UHks8X+7WL0qjzdnoYz8yzfxceSot+V9G+nJ09AGOz1rfjb7QvD4B2Wb30
/9bI7Y9+c+ijHY/feO+XZmeho2dlo17uMLrc1ewr/37PlTpLW1p7/ZF2kIKOzT3VfzyzMTs7+/Nb
nq33bL74n+5403SiI0q99xdTr21+Zd/ZX7DaISNXskceWuee1/ccB/v+V0586n/Bwhq7/StL8/kh
dnXxv2xO/Y9rIfkb7zP85fGfvuHwFda5K8eMG6zh9BT/pmjR7Dy58IVXPrd2/XpPtadqM2Glr73z
p29Y3dgwc5w1Gjg91Lte0j/HCh1toxE9lM/3QI4NEVAv5nNFa3S6eboLVuHEDPw2bMKntTvX5zZh
b8F4WhspVIpjy9rlqaGDbTEXLK/N3wBatVbJ+I/Yt303wI8SJbi0PjcNXXBdqzyAdZiZgRP887uA
u1+EwzOgd88n4cI0u9rctwV3FsPyv8u62ITivPZufc2T4os2zTzMH2ZJVtfmroEtBHb6vZPFubUa
l2O62DO/V2OKzQY97SIFvedLp470spobg57q2vLgilWFMM36FJtuT8N/gPflS1XovNxZXb9gPf2F
lcFvwFqbaJsPvP3MK5r8DpWOso/C2w+9kjDBwsNnFmEDlvPlKmxBpcLqisPUy9q/5v0Pax+6JnyT
cdU50FlfnwnL3Xif4Y9hvF/r239W8qTQ875Jnwi1lvqwdnXQaWM7/ea/LD9QvsJy/GU7NFP5MjBe
9L8Xt9pECtZgpsfsx7Wbej7Ohjarn1cgC4e+zS7/7eR/LR2/CQr7izfn/meuT3s6DLZG28HGqvbA
584PsS5RrZ3RJ/xL56fflDDBS7879AcAkxOlYzexGvHNFXuNmtIxbfRa56q4WBjI35z785C5Zq95
MXjm4Vs7NqD/Sc+yw8j7q9o/GThUhK9pi5VlsCYYJ/3wdH7w2K+xHCvttkzubhMpYOPJUbMf9936
H/8GRuzODfDSvcsfm2SVt5adYUPewtqF2sVPLL9fezoJdouYQ1wboHKBcQmHhmsV81s9aYLvgy8z
3euoVjuTAWnM+xNWnVpXC+sXVmffv/wJBTLvGjr1d1sZWP1UQN4ML59drmjf+q+NfMo6dItPP30v
rLdLz1++0VSIYO9fLLfLugCqVbhTv1iBD73ASUcVKg+urWxlre8A5/OV4aw24rBZ4hb7dehoq+Hl
I2w508I1uXPB6vGkKIF+v0v70HESqnX9tYO5ynRWZQSpa+uCHBx9WNvg4bb4OJqV5bUaE5Spa3Dq
TiuFk37CxWnquKwrREwMig+2y7qgAAfPwxlWUVW4H25xFrrakq+Uqz8zkodivr+oz7P/JA+HjPG1
eGi1Whst62sdtQPvEkchf/kQKw2TAY2fj+f79W8JovjAwEHQaofRzbP/Dp2H7/pTmfezcPAQY411
3Uk4/wa9dtdegMn6/TIq7I0uqPWzDMbGxgDsEz61b2beLEnpgToZycHtHReLYO11m+nZlyIcLLZ0
bJBMoW/4HX1dkNJMIJKC2XPL95xbhD+feCMMTv4jR/NkawL4flfps89X4emuq72Hma7d3zkHt5V1
tXPubzZv7D23oF1uwBfbY+eha/8SKwh8BbTZ68NdV5cOLya7yvv64uFzV6Fbo3sR5k8v3TMlOAHU
vP/U1PLS4Q3txsWpe5ZPs9GwH/ZBsXybAqGnp3qvTonK4tD8/svl2nkKhaEP6r8GTLjTLT633DfV
RqeTntBVjjc+mBZ95TOrobqvoNaJetYvtd2ia4djFMIPfR64ttrM68nzP1aZgb9ITQgiSAGMv7um
lK5UqGK/bC1yHVuha91yaS7sbUh7pTw6Br0by7AdpACBSE4KUgVa0yEQKAUIBEoBAoFSgECgFCDc
oCm8+XgKNPlXUQoQCN7YgRLnX/eVqnQRT1xd44P4RJD4pJI4HzZt6n7ZSmVG3iYqGQlydnInPu7d
Sc1Y9EQwiAiz9xCjxFWFIQxbZCgQDKmbthQ0DeL/7m9T4pvGzO7C9xq7+1FvKicbhYwEOQeKOPVS
0T4IiN8UZe8hZhSBfzmQYbOg+ssoBG0jBUaEdSPGutGX7UttwDIb2XjAjX/aN2qn9w95ZjfxSkt4
oHl+ijKytYZMqhqi1DsZ6ex7ulvQwB8qOaFpqe+1EIbbqPPTXfKmTAqMvkf4gY0f6ijXPc07xOmm
1N/xXGMx5YbKoF5h5WLk6enPlt6lklGA2ubIk/0ukfVLGi0usJmWmEO9pORO7aQvDQ1zQLfVm7z8
ZNTkykWL0LAqI/5ZnYi6R8OFIaEZBZWYiApAZBXrqPIxdE8/w8QlWtq8StVnOEQyGpG1POS1cbWZ
iMY6bTXa44xuJO6AjeVJAjpsXMqHd63j32FApLYuIPLpkUSYRal/XejWCwTaBxUurQUdhM8o8qZW
hGkptu2bAJXRu5pAtMEeUciGKRU+sL8Jtzmod1IgIR1P1OEIDeiGRN6BBUIWKLxhPT2eMbrNR3qy
S97kX80EaBbm7MzpAealqXX4NFrPsE6JX1MJUliosfIkVNz/zRsKKonDopmR70ao2sTxEiTMHBVf
9u4Psc4TUNFcatIe6wJzQaSuBjo/lkTnv0FlswGSAcVqyL+AkmYet3AboKmMYqFLt+nvYJRE457b
M2xVHTVCMqBYmQYHidYJQXqqQQwF2a51EZlv0vryNkAyKG2mQdot1HtJWhmRmEhuR0lodEeMtr64
UUgGpM0AAiEU36jjuvUTZwvng8gkA9KiFCAEwyWJ+kJCekDMM3ZQWpQCRJN6YApLgrhXXehfgBCP
7w31SNp6IaAxFKuDeJOILZCj7WL7zACobx+ct64TjED8Y5/bg8zsn3cVQHOEZpacyitPx0WiAa2o
sSV1IyQDipVRWxA12ZfCjGNEJvzgskp2G2DIzf5drgJosN+MXkQipocmrbUaeYs0XyyRRkQptT+o
aV1HrdvU6mPGU/A8Md9158We8A+tfGmgjFHSjNKJ/R4RDRlxJ7J9Bojt3eL+qc7lGEYCvbpcngq8
PwJvd+9XjUjwaOFz3/En9xj6oVAgokuBZKpyGwgRt2FwY85foQahohUJBbUfpNBAE9GoFJgDbCRL
qqB+R+WdUjJWE7HvsoKohZrNIRChUkDkq+UwfYUG9leiIEsRLd7C3kFNKD4YYUAivzUW5XZkIuMn
RyZ65vn8wgmyD3HSTPRNHaHSzW1kho713tNeeL+EhiYKXCS3BmPtR6R28vSJWsfAnPJrgek6RT2b
6ruRxofdq63v/m/cNaGUCPLyZmzka2wYaTtHlAaN9G6qAMFKjpmS+m6gMMSHgWIuX4HCANSLMFXK
FaeMAVyLl9Z7N4xn88V+Y6Ct5LVnDP2FPHuDpc89yv7tzpW1CGADpVKVfStny6J4i+PFbIFAYQrq
BSuNRYQUoJLPFY1AGr2nT0BxYd140pfPm3d7oVos9I268p8qWrmAxbd5T+evUzC0EkKcD2KvQs3v
VlLnAf+EEHORTPhkhM8BrHytd4l538cJ947vJAqBGHBc8Cwi4sPvltfLy1DbgDdk4fbCeuF251HX
1+Gx7rUfvMf4tnHZfLb0w7WF+1hbfKf39wH20vXvabEs135Zeox9+3Y9t1dA5N3VemkFclfh6bwv
zSVYKq1XjXYd0eKbF80AS9cvL+ghh5/aXIRv5C9p8Ym5d29/5Ulb67H4Nu7p/G0/C4qIK16cCmJa
GOgRAr84D9Vh+God1vNQmIYZLlzidAX+ql57y1eMb1cq5rNVNl5PA6wfnltlvT8L71zTn84/wR4d
hplVAZFaUSNy6p/BE1lvmpkKZOu12qrnDYaLlaIW7bnv8y8BfPNCRYuayb1LKydsVi2+jXs6f13F
bdcexQRTIwJwYGxWC51e39uVuWn20T/eyCzCHb8Hj3RehwPsPvs78HsAy4XMn5AVPflL1rP63kee
vmlWS8xwx4EDB17a1J7CK5t6BplNP5Hql1eLN81+/rXn/s9VKw1HZPLR/OdXu/Tk7ObsrHbbeKJ9
/Pzlhx6BV/4Iug7McvlrT41czNsab+xe16bBH1rTISKgd2u+G6DSRVg3nKxC1eg+Vhy77PJrpSXj
sg7VLuON64evgp6YYWJsbEwLodYP1Q4jAxGRX+3Y+wwj0tNXM9JsuYgcXblc+ph+NaEtBMbHXe92
FN/E/jEy5vKvc5Qsvus6Ezp/KAWICNiYr2kaTe4dc6zP/184yBSOyVrVUjoLtcoTHzYu98LBnH7x
L668RdPNs+cHmPqxVodnSprOA7ewN1d/BgfzAiLX/35ai1T+3w9XjDTsxYnx6n5rcq9VOr6qX51+
sAbjj111v7yweRlWb4b94678e6FoUzL5Nu/p/KEUICJgcc/7tB7zujYM07vya2yNttB741fNp3tI
7uSHzL3H/PpF/WJwzz7tjeLnr7K0G325z2qR4RfuXvkJ+3Z3bv2KgEj5Izdqr/xgfMZOs3hyX5f1
9D3ZZWNFfOJDvaMnP+RVeX9wCH6ynu/sdOW/WBiwKZl8m/d0/jDGJSKJtXTKQSuhsroSITVKASIB
5NfSpN6z2tF5NYtSgEBEAK4LEAiUAgQCpQCBQClAIFAKEAiUAgQCpQCBQClAIP4/C2IekEGID1AA
AAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2008-07-18 14:54:10 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.06" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.6 Initial claudication distance (expressed as kilocalories) after 24 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwUAAADwCAMAAABmDDh8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2008-07-18 14:54:36 +0100" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.07" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.7 Initial claudication distance (expressed as kilocalories) after 12 to 16 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwUAAAEACAMAAADV6SrRAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2008-07-18 14:54:43 +0100" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-001.08" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.8 Initial claudication distance (expresses as kilocalories) after 6 to 8 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwUAAADQCAMAAABhoD1KAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2008-07-18 14:54:51 +0100" MODIFIED_BY="[Empty name]" NO="11" REF_ID="CMP-001.09" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.9 Ankle brachial index and ankle pressure at the end of study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAw4AAADgCAMAAACdOsEQAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2008-08-21 13:57:53 +0100" MODIFIED_BY="[Empty name]" NO="12" REF_ID="CMP-001.10" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.10 Quality of life (expressed as a Visual Analogue Scale for complaints).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxAAAADACAMAAACj8XV9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2008-12-31 10:41:26 +0000" MODIFIED_BY="[Empty name]" NO="13" REF_ID="CMP-001.01" SETTINGS="SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.1 Absolute claudication distance (expressed as kilocalories) at the end of the study. On the horizontal axis the effect estimate of Ginkgo biloba versus placebo on the absolute claudication distance at the end of the study is presented as the mean difference. The vertical axis presents the standard error of the intervention effect on a reversed scale.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2008-12-31 10:40:00 +0000" MODIFIED_BY="[Empty name]" NO="14" REF_ID="CMP-001.02" SETTINGS="SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.2 Absolute claudication distance (expressed as kilocalories) after 24 weeks. On the horizontal axis the effect estimate of Ginkgo biloba versus placebo on the absolute claudication distance after 24 weeks is presented as the mean difference. The vertical axis presents the standard error of the intervention effect on a reversed scale.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-04-22 12:03:39 +0100" MODIFIED_BY="Heather  Maxwell">
<APPENDIX ID="APP-01" MODIFIED="2013-04-22 12:03:39 +0100" MODIFIED_BY="Heather  Maxwell" NO="1">
<TITLE MODIFIED="2013-04-22 12:02:14 +0100" MODIFIED_BY="Heather  Maxwell">2013 CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-22 12:03:39 +0100" MODIFIED_BY="Heather  Maxwell">
<TABLE COLS="3" ROWS="31">
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>893</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriolosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis Obliterans] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MeSH descriptor: [Atherosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>382</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MeSH descriptor: [Arterial Occlusive Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>755</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>MeSH descriptor: [Intermittent Claudication] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>711</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>MeSH descriptor: [Ischemia] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>753</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>MeSH descriptor: [Peripheral Vascular Diseases] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>2150</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>381</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>(atherosclero* or arteriosclero* or PVD or PAOD or PAD) </P>
</TD>
<TD ALIGN="RIGHT">
<P>17195</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>(arter*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>4872</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>(vascular) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>1378</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>(vein*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>713</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>(veno*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>976</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>(peripher*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>1358</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>peripheral near/3 dis* </P>
</TD>
<TD ALIGN="RIGHT">
<P>3243</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>arteriopathic </P>
</TD>
<TD ALIGN="RIGHT">
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>(claudic* or hinken*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>1436</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>(isch* or CLI) </P>
</TD>
<TD ALIGN="RIGHT">
<P>16827</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>dysvascular* </P>
</TD>
<TD ALIGN="RIGHT">
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>leg near/4 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>176</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>limb near/4 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>228</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>(lower near/3 extrem*) near/4 (obstruct* or occlus* or steno* or block* or obliter*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>137</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>(aort* or iliac or femoral or popliteal or femoropop* or fempop* or crural) near/3 (obstruct* or occlus*) </P>
</TD>
<TD ALIGN="RIGHT">
<P>322</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 </P>
</TD>
<TD ALIGN="RIGHT">
<P>39158</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>MeSH descriptor: [Ginkgo biloba] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>231</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>(ginkgo* or gingko* or gingkco* or ginko* or gingho or gincosan):ti,ab,kw </P>
</TD>
<TD ALIGN="RIGHT">
<P>654</P>
</TD>
</TR>
<TR>
<TD>
<P>#28</P>
</TD>
<TD>
<P>(bilobalid* or tebonin* or kaveri* or tanakan or tanakene or tebokan or rokan or supergin* or (li next 1370)):ti,ab,kw </P>
</TD>
<TD ALIGN="RIGHT">
<P>57</P>
</TD>
</TR>
<TR>
<TD>
<P>#29</P>
</TD>
<TD>
<P>(EGB761 or "EGB 761" or EGB-761):ti,ab,kw </P>
</TD>
<TD ALIGN="RIGHT">
<P>134</P>
</TD>
</TR>
<TR>
<TD>
<P>#30</P>
</TD>
<TD>
<P>#26 or #27 or #28 or #29 </P>
</TD>
<TD ALIGN="RIGHT">
<P>670</P>
</TD>
</TR>
<TR>
<TD>
<P>#31</P>
</TD>
<TD>
<P>#25 and #30 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>90</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-02-10 15:05:24 +0000" MODIFIED_BY="Heather  Maxwell" NO="2">
<TITLE MODIFIED="2009-02-10 14:47:51 +0000" MODIFIED_BY="Heather  Maxwell">Search strategy used by authors to search MEDLINE and EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-10 14:48:21 +0000" MODIFIED_BY="Heather  Maxwell">
<P>#1 Peripheral arterial disease<BR/>#2 Peripheral arterial occlusive disease<BR/>#3 PAD<BR/>#4 Intermittent claudication<BR/>#5 (#1 OR #2 OR #3 OR #4)<BR/>#6 Ginkgo biloba<BR/>#7 Egb 761<BR/>#8 Tavonin<BR/>#9 Tebonin<BR/>#10 Rokan<BR/>#11 (#6 OR #7 OR #8 OR #9 OR #10)<BR/>#12 (#5 AND #11)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>


<EXTENSION ID="AFF_z1301301227513793614450285216298_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="z1301301227513793614450285216298"><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>CAPHRI Research School, Maastricht University</ORGANISATION><CITY>Maastricht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></ALIAS></EXTENSION><EXTENSION ID="AFF_17950_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="17950"><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>CAPHRI Research School, Maastricht University</ORGANISATION><CITY>Maastricht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>